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The polyketide (PK) class of natural products constitutes an abundant array of 
secondary metabolites produced in microorganisms, many of which possess potential 
medicinal value, especially in the area of oncology. Polyketides are assembled 
biosynthetically via the megaenzymes polyketide synthases (PKSs) through an 
assembly line process of stepwise condensations of simple malonic acid building blocks 
derived from primary metabolism. Despite the usefulness of natural products in 
medicine, the development of polyketide natural products into new drugs is often 
hindered by their suboptimal pharmacological properties, highlighting the need for their 
modification by medicinal chemistry. However, low natural abundance and high 
structural complexity often necessitates lengthy and expensive synthetic routes to 
natural product analogs, thus impeding their clinical development. A promising method 
for expanding the chemical diversity within polyketide natural products is PKS 
bioengineering, whereby natural product analogs are generated by engineering new 
functionality into the enzymes responsible for their production instead of through 
synthetic derivatization. While notable successes in PKS engineering have been 
achieved, many attempts result in decreased product yields or fail to produce the 
predicted molecules entirely.  
The studies in this thesis focus on investigating the structural and mechanistic 
parameters that govern PKS catalysis in order to increase the potential of harnessing 
these enzymes as biocatalysts for the production of new polyketide analogs. First, a 
series of engineered PKS modules was generated by combining modules from the 
pikromycin, erythromycin, and juvenimycin biosynthetic pathways with non-native TE 
domains and analyzed for substrate flexibility in vitro. The results from this study 
implicated the TE domain as the dominant catalytic bottleneck in the full-module 
processing of unnatural substrates. We next focused our investigations on probing the 
TE directly as an excised domain, subsequently confirming the previously observed
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catalytic bottleneck. Mutational analysis of the Pik TE domain resulted in an engineered 
variant (S148C) with improved substrate flexibility and catalytic efficiency, which 
eliminated the aforementioned bottleneck and allowed for the production of 
diastereomeric macrolactone analogs. Finally, we performed molecular dynamics (MD) 
simulations coupled with quantum mechanical (QM) calculations of the native and 
engineered TE domains to provide a mechanistic rational for our experimental 
observations. Taken together, the results herein provide further insight into the catalytic 
and mechanistic parameters that govern the productive functioning of engineered PKSs. 
Our identification of the thioesterase domain as a key catalytic bottleneck in the 
processing of unnatural substrates builds the groundwork for future engineering of PKS 
TE domains in order to generate more flexible catalysts for the production of novel 

























Therapeutic natural products  
Natural products (secondary metabolites) are organic compounds which are not 
directly required for the normal growth, development, or reproduction of the producing 
organism, yet provide a selective long-term advantage in their survival.1 Human use of 
natural products from both marine and terrestrial sources as therapeutic agents to 
combat a diverse array of diseases predates recorded human history. Some of the 
earliest recorded examples of the medicinal use of natural products come from 
cuneiform inscriptions on clay tablets from Mesopotamia (2600 B.C.) which documented 
the therapeutic application of many plant derived substances including Cupressus 
sempervirens (Cypress) and Commiphora species (myrrh) oils in the treatment of 
respiratory ailments.2 
Historically, the use of natural products as medicines has been in the form of 
crude traditional medicines, remedies, and potions with the bioactive component(s) 
unidentified.  The arrival of modern chemistry starting in the 18th century marked a new 
era in the study and use of natural products. Technological advances in analytical and 
structural chemistry made possible the purification and characterization of the individual 
components of natural product extracts. This shift in paradigm is exemplified by the 
German pharmacist Friedrich Wilhelm Sertürner’s isolation of morphine from opium, 
constituting the first pure natural product medicine.3 Since that time, Western 
pharmaceutical companies have pursued natural product drug discovery and 
development extensively, resulting in numerous clinically successful natural product 




include the antibiotic (erythromycin A), anticancer (epothilone), cholesterol-lowering 
agent (lovastatin), antiparasitic (avermectin), insecticide (spinosyn A), anagelsic 
(morphine), and immunosuppressant (rapamycin) (Figure 1.1). Highlighting the 
ubiquitous use of natural product derived molecules in the clinic, Newman et al. noted in 
a recent review1 that of the 246 small molecule therapeutic agents approved worldwide 
from the 1930s to 2014 in the area of oncology alone, 160 (77%) of these were either 
natural products or synthetic compounds inspired by natural products.    
Despite this clinical success, pharmaceutical research into natural products has 
largely declined over the past two decades.2 A number of factors contribute to this 
contraction, with two prominent developments being the introduction of high-throughput 
screening (HTS) methods against specific molecular targets and the development of 
combinatorial chemistry. HTS methods have allowed for the focused targeting of a 
growing number of precise molecular targets, however, these assays are typically 
incompatible with natural product extracts and have traditionally relied on synthetic 
libraries. Concomitant with the development of HTS methods was the introduction of 
combinatorial chemistry which promised to supply HTS assays with chemical libraries of 
simpler, more drug-like molecules. As a result of these technological changes, the 
current climate in pharmaceutical dug discovery relies on rapid screening of simple 
Figure 1.1 Examples of clinically valuable bioactive natural products. 
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chemical libraries, initial hit identification, followed by significant medicinal chemistry on 
the lead molecule to establish structure-activity relationships (SAR). Thus, the 
comparably resource intensive natural product drug discovery model involving extract-
library preparation and screening, bioassay-guided isolation, structure elucidation, and 
analog generation has been largely abandoned.  
However, this shift away from natural products drug discovery has resulted in 
significant negative consequences. It is now well recognized that synthetic chemical 
libraries contain molecules that are economically efficient to generate, and thus 
significantly less complex than their natural products counterparts.3 Compared to 
synthetic chemical libraries, natural product-structures possess increased levels of 
chemical diversity arising from their high molecular mass, increased steric complexity 
from a large number of chiral centers, increased molecular flexibility from a large 
number of rotatable bonds, and unique distribution of heteroatoms.4 These molecular 
properties combined with their biochemical specificity lend natural products as favorable 
lead structures for drug discovery. Natural products serve as excellent lead compounds 
in drug discovery as they have high chemical diversity, biochemical specificity and other 
favorable molecular properties.2 Additionally, natural products often contain “privileged 
scaffolds” referring to the fact that natural products have been evolved under selective 
pressure for interaction with a wide variety of biological targets for a specific purpose.2,5 
It is this evolutionarily optimized scaffold that enables many natural products to interact 
with challenging molecular targets and imparts them with their exquisite biological 
activities, thus providing an advantage over synthetic libraries often employed in drug 
discovery efforts. 
 
Polyketide natural products  
The polyketide class of natural products constitutes an abundant array of 
secondary metabolites, many of which possess therapeutic or industrial value1, 
constituting sales in the billions of dollars.6 Polyketides represent complex chemical 
scaffolds arising from their highly diverse composition of functional groups. The 
manifold skeletal and stereochemical complexity decorating polyketides, along with their 
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potent bioactivities, has made them a keen area of interest for a broad range of 
scientific disciplines.7 
Of particular allure, polyketides often contain a macrocylic core, defined as a ring 
architecture containing 12 or more atoms.8 Macrocyclic polyketides (e.g. all except 
lovastatin and morphine, Figure 1.1) are of great interest to medicinal chemists as the 
conformational preorganization of these large rings allows for the precise display of key 
functional groups to interact with challenging drug targets, such as protein-protein 
interactions.8 Despite the proven therapeutic potential of macrocyclic natural products 
(there are currently >100 marketed macrocyclic drugs8), macrocyclic compounds remain 
an under-explored section of drug discovery.  One significant contributing factor to this 
lack of exploration is the formidable challenge in generating macrocyclic compounds 
from their linear precursors. Regio- and stereoselective ring-closures are notoriously 
difficult and often require dilute reactions conditions with large volumes and low reactant 
concentrations.8,9  Furthermore, as evidenced from the pioneering total synthesis of 
Erythromycin A10, macrolactonization of acyclic analogs is often unachievable even in 
optimized conditions as the productive conformations necessary for the linear substrate 
to achieve for ring closure are likely perturbed from the natural “competent 
conformation”.11 These synthetic hurdles to the production of macrocyclic polyketide 
analogs thus limit their development into clinically useful therapeutics, despite their 
potential for interacting with challenging macromolecular targets.  
 
Type I polyketide biosynthesis 
Polyketides are assembled biosynthetically via the megaenzymes polyketide 
synthases (PKS) through an assembly line process of stepwise condensations of simple 
monomer building blocks in a manner analogous to fatty acid biosynthesis.7 Modular 
type I polyketide synthases are large bacterial proteins that form complexes likened to 
molecular assembly lines that are responsible for the production of numerous 
therapeutically valuable polyketide natural products.12 Advances in microbial genetics 
allowed for the pioneering sequence elucidation of the erythromycin biosynthetic 
pathway that produces the polyketide core of the erythromycin A antibiotic.12-14 This 
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initial sequence analysis, as well as the many subsequent reports following it, allowed 
for the characterization of the mechanism through which type I PKS biosynthesis 
occurs: Each PKS module is responsible for catalyzing the two-carbon elongation of a 
growing polyketide chain and requires a minimum of three enzymatic domains (Figure 
1.2): An acyltransferase (AT) domain which selects an appropriate acyl-coenzyme A 
extender unit and transfers it to the acyl carrier protein (ACP) which presents the loaded 
extender unit to the ketosynthase (KS) domain that accepts the upstream acyl chain 
Figure 1.2 Type I polyketide synthase catalytic cycle. A malonyl CoA extender unit (blue) is 
incorporated into the growing nascent polyketide chain (red) through the successive action of three 
core domains. The extended intermediate is then available for additional reductive processing at the 
β-keto position by a combination of three additional reductive domains.  
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and catalyzes a decarboxylative Claisen condensation to incorporate the extender unit 
into the growing acyl chain.12 Additionally, PKS modules may also contain a 
combination of tailoring domains including a ketoreductase (KR), dehydratase (DH), and 
enoyl reductase (ER) which reduce the β-keto position to a hydroxyl, alkene, or alkane, 
respectively. Furthermore, the terminal module often contains a thioesterase (TE) 
domain which is responsible for the regio- and stereoselective offloading of the acyl 
intermediate either as a linear acid or macrolactone.15 
 
The pikromycin biosynthetic pathway: a model system 
The pikromycin biosynthetic pathway (Pik) is a representative type I PKS system 
that has served as a workhorse for the Sherman Lab for nearly 20 years.16 The Pik 
pathway is unique in its ability to produce two macrocyclic polyketides, the 12-
membered ring 10-deoxymethnolide (10-dml) and the 14-membered ring narbonolide 
(Figure 1.3). Both macrolactone products are then further diversified by the processing 
of post-assembly line tailoring enzymes to yield a suite of five macrolide natural 
products.17 The inherent catalytic flexibility of the Pik pathway renders it an attractive 
target for engineering studies. Sequencing analysis of Streptomyces venezuelae (S. 
Venezuelae) revealed the genetic architecture of the Pik pathway.16 The Pik 
biosynthetic pathway is composed of 18 clustered genes: two ribosomal methyl 
transferases, four polyketide synthases, a type II thioesterase, nine genes involved in 
desosamine biosynthesis and attachment, a p450, and a pathway regulator.  
In a landmark study, four laboratories at the University of Michigan collaborated 
on solving the first three-dimensional structure of an entire intact PKS module through 
the use of cryo-electron microscopy (cryo-EM).18,19 In this pioneering work, Dutta et al. 
subjected PikAIII (Figure 1.3) to a painstakingly in-depth purification strategy followed 
by cryo-EM analysis and the selection of hundreds of thousands of particles to yield a 
final set of structures with resolutions of 7 to 10 Å. In contrast to long-standing 
expectations, fitting the spheroid particles to a model system derived from the crystal 
structures of several homologous excised domains from the DEBS biosynthetic pathway 
yielded a three-dimensional reconstruction of PikAIII as a homodimer aligned head-to-
7 
 
head and tail-to-tail in a horseshoe shape which encloses a single inner reaction 
chamber composed of each domain active site.18 Furthermore, by making use of the 
natural substrate (Pik pentaketide) and extender unit (methylmalonyl-coenzyme A) 
Whicher et al. successfully determined the cryo-EM structure of PikAIII in three key 
biochemical states of its catalytic cycle representing a single round of polyketide chain 
extension and reduction19 (Figure 1.3). Comparing the overall architecture of PikAIII in 
its various catalytic states provided significant insight into the dramatic conformational 
rearrangements that take place to allow for productive catalysis. These flagship 
Figure 1.3 The pikromycin (Pik) biosynthetic pathway.  The macrolactones 10-dml and narbonolide 
generated by the Pik PKS undergo further tailoring to the macrolides methymycin and pikromycin, 
respectively. Open reading frames are represented as arrows while enzymatic domains are 
represented as boxes. KS
Q
, KS-like domain; KR
*
, inactive KR. The three-dimensional cryo-EM 




structural studies of PikAIII provide the first ever structural and dynamic blueprint for 
future PKS bioengineering efforts.  
 
Engineering new polyketides 
Despite the usefulness of polyketide natural products in medicine, the 
development of polyketides into new drugs is often hindered by their need for synthetic 
derivatization. Although many polyketide natural products possess favorable 
bioactivities, their development into clinically viable therapeutics often represents a 
significant challenge due to inherently poor pharmacological properties. Thus it is often 
necessary to optimize polyketide natural products for therapeutic development through 
the generation of analogs. However, the high structural complexity of polyketide natural 
products limits their chemical space accessible by synthetic chemistry and necessitates 
lengthy and expensive synthetic routes.20,21 Traditionally, natural product analogs have 
been generated through semi-synthesis, whereby a naturally occurring molecular entity 
is isolated from the producing organism and further derivitized through synthetic 
chemistry (1, Figure 1.4). While providing notable successes, semi-synthetic strategies 
often require lengthy and expensive routes that are constrained by accessible 
functionality and reactivity. Alternatively, the collinear relationship between PKS genetic 
sequence and polyketide product provides an additional route to polyketide analogs.7,12 
Biosynthetic pathway engineering represents an attractive method for increasing the 
chemical diversity of polyketide natural products whereby novel natural product analogs 
are generated by manipulation of the enzymes responsible for their biosynthesis.22 
Mutasynthesis uses synthetic starter units that chemically complement early pathway 
knockouts in native or heterologous producers as a means to generate natural product 
analogs23,24 (2, Figure 1.4). Combinatorial biosynthesis generates polyketide chemical 
diversity by engineering of the PKS biosynthetic enzymes responsible for their 
production.6,25,26 The strategies utilized in combinatorial biosynthesis include alterations 
at both the individual domain level to modify the functional groups present on the 




Figure 1.4 Laboratory methods for generating polyketide analogs. Boxes represent enzymatic 
domains while letters represent chemical intermediates. Figure adapted from reference 23.  
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length (3, Figure 1.4). New chemical diversity is achieved through a number of different 
forms of PKS bioengineering that alter the length of the polyketide chain (determined by 
the number of modules that comprise the polyketide synthase), the choice of primer and 
extender units (controlled by the AT domains), the degree of reduction of the polyketide 
backbone (determined by the set of enzyme domains present in each module), and the 
stereochemistry at centers carrying alkyl and hydroxyl substituents (controlled by 
enzyme domains that are responsible for generating the stereocenter in question). 
Although combinatorial biosynthesis has been successfully pursued by many 
research groups for the production of polyketide analog libraries, these bioengineering 
attempts are often accompanied by a concomitant decrease in product yields or fail to 
produce new molecules entirely.27-29 The mechanistic rational for the diminished activity 
observed from PKS engineering attempts remains unclear. To date, the majority of PKS 
engineering studies have targeted genetic modifications in early pathway PKS 
modules.27,28,30-33 As a result it is unknown whether the attenuated product formation 
results from the engineered module or the downstream modules that must accept and 
process the unnatural intermediate. A significant hindrance in the mechanistic 
troubleshooting of these PKS engineering studies is the in vivo context in which they 
were performed which prevents the isolation and characterization of shunt products 
arising from catalytic points of failure. Thus for a more general framework for rational 
engineering of efficient PKSs, it is critical moving forward for more targeted 
investigations to probe the catalytic details of individual domains. 
 
Thesis outline  
Given the interest in generating natural product analogs to support drug 
discovery efforts, and the significant synthetic challenges encountered in this pursuit, 
we sought to further our knowledge of PKS structure and function in efforts to harness 
them as biocatalysts for the biosynthetic production of polyketide analogs. Due to the 
innate catalytic flexibility of the pikromycin biosynthetic machinery, we chose to utilize 
Pik as a model system for performing these investigations. The studies presented in this 
dissertation aim to unveil the catalytic parameters that govern PKS function by directly 
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probing PKS enzymatic domains and modules in vitro. To begin, the studies in Chapter 
II focus on identifying catalytic bottlenecks in the processing of unnatural substrates 
through the use of in vitro methods that simulate combinatorial biosynthesis. Taking 
advantage of previously optimized in vitro PKS biochemistry conditions, we employed a 
series of Pik pentaketide analogs that mimic unnatural intermediates arising from 
upstream PKS engineering modifications, and use them to probe the substrate flexibility 
of PikAIII-TE.  Analysis of the resulting shunt products indicated the TE domain as a key 
catalytic bottleneck in the processing of unnatural substrates. To test this hypothesis, 
we next generated a series of hybrid type I PKS modules containing TE domains from 
three homologous pathways and used these hybrid PKS modules to demonstrate the 
critical role of the TE domain in the context of PKS engineering. Furthermore, we next 
applied these catalytic insights towards the chemoenzymatic production of 14-
membered macrolactone analogs. The advances made in Chapter II have been partially 
reported in references 35.  
Chapter III builds upon the TE gatekeeper hypothesis generated in Chapter II by 
focusing studies on the TE directly as an excised domain. Prior to enzymatic analysis, it 
was necessary to stabilize the Pik TE native substrate (Pik hexaketide). This was 
accomplished through the use of two distinct protection strategies, including a 
photocleavable 2-nitrobenzyloxymethyl ether protecting group. These advances in 
substrate stabilization allowed for the evaluation of a panel of substrate esters in order 
to optimize diffusive loading onto Pik TE. This evaluation revealed a dramatic variation 
in catalytic processing with each protected hexaketide. Cloning, expression, and 
purification of a series of TE domain mutants allowed for probing the catalytic 
parameters required for TE catalyzed macrolactonization reactions and provided the 
serendipitous discovery of a Pik TE mutant (S148C) that is a more efficient 
macrolactonization catalyst. Finally, incorporation of this engineered TE into PikAIII-TE 
relieved the catalytic bottleneck observed in Chapter I, allowing for the processing of 
two unnatural macrolactones. The findings from this chapter have been reported in 
references 34 and 36.  
Chapter IV concludes this dissertation with a thorough investigation into the 
increased catalytic efficiency observed with Pik TE S148C. Working towards a structural 
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analysis of Pik TE, a double mutant strategy was successfully employed to stably 
capture the protein as an acyl-enzyme intermediate. However, all attempts to crystalize 
this labeled mutant to date have failed to yield suitable material for X-ray 
crystallography. Thus we pursued an alternative strategy using computational 
techniques and the available three-dimensional structures of Pik TE as an apoprotein to 
model the catalytic steps post acyl-enzyme formation. Using a combination of molecular 
dynamics (MD) simulations along with quantum mechanical (QM) calculations, we 
provide further insight into the catalytic parameters governing macrocyclization in Pik 
TE and describe a mechanistic rational for the previously observed strict substrate 
stereospecificity. We next perform analogous serine to cysteine mutations in 
homologous type I TE domains to preliminarily determine the generality of this mutation, 
and discuss the biosynthetic implications of naturally occurring TE domains with a 
native cysteine nucleophile. The findings from this chapter have been reported in 
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The biocatalytic production of polyketide analogs through genetic engineering of 
PKS biosynthetic pathways is a long-standing goal.1-4 Several successful examples 
have been reported by Kosan Biosciences, highlighting the ability to generate libraries 
of polyketide analogs through modular PKS engineering.5-7 These studies utilized 
canonical combinatorial biosynthesis strategies by incorporating AT and KR domain 
substitutions into modules 2, 5, and 6 of the 6-deoxyerythronolide B (DEBS) 
biosynthetic pathway followed by overexpression in heterologous Streptomyces or E. 
coli hosts to generate a suite of 6-deoxyerythronolide (6-dEB) analogs. While these 
PKS engineering studies introduced an impressive array of functional and skeletal 
diversity into the 6-dEB macrolactone core, they also highlighted the significant 
shortcomings with this approach as the yields of the 14-membered macrolactone 
analogs dropped precipitously with the highest being only 3.5% relative to 6-dEB 
production.5  
Furthermore, a perhaps more significant limitation of these studies is the in vivo 
experimental design which precludes the identification of catalytic bottlenecks due to the 
difficulties encountered with isolating shunt products from the complex fermentation 
medium. Thus the biochemical basis for the decreased product titers or entirely failed 
engineered PKS pathways remains elusive. These engineering strategies often times 
target early pathway domains or modules5,6,8-11 and the resulting unnatural intermediate 
must then be effectively processed by all downstream enzymatic domains for the 
successful production of the anticipated natural product analog. Therefore, in the 
absence of precise mechanistic information, it is unclear whether the attenuated product 
formation stems from the engineered module or the downstream modules (or both) that 
must accept and process the resulting unnatural intermediates. This uncertainty 
highlights the need for more targeted investigations into PKS catalysis to provide a 
more general framework for the rational engineering of efficient PKS pathways.  
Towards this goal, investigations in the Sherman lab have evolved over the past 
two decades from in vivo studies relying on genetic alterations to targeted in vitro 
experiments directly probing the mechanistic underpinning of PKS catalytic domains. A 
particularly productive strategy has been the application of synthetic chemistry to 
18 
 
provide full length chain elongation intermediates for probing PKS machinery with its 
native substrate. Prior to this advancement, the more easily synthetically achievable 
diketide and triketide N-acetylcysteamine thioester substrates were employed for 
studying PKS catalysis in vitro. While the use of these simpler substrates has provided 
many fundamental insights into the nature of PKS catalysis, it was quickly noted that 
their relevance in determining the substrate selectivity of late stage PKS machinery was 
inadequate as these simplified substrates do not adequately represent the natural chain 
elongation intermediates processed by the enzymatic domains in question.12 Although it 
requires a significant synthetic investment, it is essential to study these enzymes with 
fully elaborated polyketide chain elongation intermediates to adequately understand the 
complex kinetic and mechanistic parameters governing PKS catalysis. Recent work in 
the Sherman lab has focused especially on late stage biosynthetic enzymes as they are 
responsible for the final processing of the most mature biosynthetic intermediates and 
thus may possess the strictest level of substrate specificity.12 Efforts by Mortison et al13. 
investigating the substrate flexibility of the homologous penultimate modules from the 
Pik and DEBS pathways highlighted the high level of substrate specificity inherent in 
these final PKS modules. Consistent with previous reports, PikAIII-TE paired with its 
native substrate Pik pentaketide was able to efficiently generate 10-dml, while DEBS 
Mod5-TE paired with its native substrate DEBS pentaketide produced the anticipated 
12-membered macrolactone. However, when tested for the ability to process the non-
native yet similar pentaketides from the noncognate pathways, no macrolactone 
products were identified, indicating a low level of substrate flexibility within these late 
stage PKS modules.  
 
Probing PikAIII-TE with unnatural pentaketides 
Developing this paradigm further, Hansen et al. pursued a substrate-centric 
strategy to “simulate late stage PKS engineering” which provided increased mechanistic 
insight into PKS catalysis with unnatural substrates.14  In this approach, two classes of 
Pik pentaketides were generated; aliphatic truncations and diastereomers that mimic 
the upstream engineering of early pathway AT or KR domains, respectively to probe the 
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substrate flexibility of the late stage module PikAIII-TE.12,13,15 PikAIII-TE displayed 
moderate flexibility for truncated substrates (2-5, Scheme 2.1) and was able to process 
C-10 desmethyl 2 with near wild type efficiency (56% yield), followed by C-8 desmethyl 
3 with a 39% yield. However, C-8,10 didesmethyl 4 and C-9 desethyl 5 afforded poor 
conversion to the expected products (17% and 9% yield, respectively). PikAIII-TE failed 
to yield detectable macrocyclic products entirely from diastereomers 11-13 designed to 
interrogate the PKS flexibility toward substrates bearing unnatural C-8 and C-9 
stereocenters (Scheme 2.2). HPLC purification of the isolable products from these 
reactions followed by 1H NMR analysis revealed small quantities of extended material 
off-loaded from the PKS assembly line as linear shunt products (14-19, Scheme 2.2).  
Scheme 2.1 Evaluation of PikAIII-TE with a panel of truncated pentaketides. These reactions were 
performed to interrogate the substrate flexibility of PikAIII-TE for pentaketides that simulate the 
upstream engineering of early pathway AT domains Enzymatic reaction conditions: 4 mM Pik 
pentaketide, 40 mM (10equiv) MM-NAC, 20 mM (5 equiv) 2-vinylpyridine, 0.4 mM (10 mol%) NADP+, 
10 mM (2.5 equiv) glucose-6-phosphate, glucose-6-phosphate dehydrogenase (2 units/mL), 4 μM (0.1 




The severe drop in product yields from the native pentaketide 1 to the truncated 
substrates 4 and 5 was surprising as these modifications are distal from the location of 
the Claisen condensation and β-keto reduction catalyzed by the KS and KR domains, 
respectively. We interpreted this to suggest that the TE domain responsible for the 
release of the macrolactone from the PKS assembly line could be responsible for the 
compromised catalytic efficiency with the truncated substrates 2-5. The total failure in 
processing of diastereomer 11, which differs from the native pentaketide 1 only by 
epimerization of the C-9 hydroxyl group which serves as the nucleophile during 
macrolactonization, further implicated the TE domain as the catalytic point of failure as 
previous studies from the DEBS TE have revealed a strict stereospecificity in the 
macrolactonization of unnatural substrates.16 NMR and MS analysis of the reaction 
products from a large scale reaction with 11 produced the shunt products 14 and 15 
which were successfully extended by the KS domain and thus we hypothesized that 
these products resulted from stalling and premature off-loading from the PKS via 
hydrolysis and subsequent decarboxylation (Figure 2.1). Isolation of these extended yet 
linear off loaded intermediates indicates the TE domain as the dominant catalytic 
bottleneck to the formation of macrocyclic products. This hypothesis was then confirmed 
by synthesis of the corresponding C-11-epimerized hexaketide and subsequent probing 
Scheme 2.2 Reaction of PikAIII-TE with a panel of stereoisomer pentaketides. These reactions were 
performed to interrogate the substrate flexibility of PikAIII-TE for pentaketides that simulate the 
upstream engineering of early pathway KR domains Enzymatic reaction conditions: 4 mM Pik 
pentaketide, 40 mM (10 equiv) MM-NAC, 20 mM (5 equiv) 2-vinylpyridine, 0.4 mM (10 mol %) NADP+, 
10 mM (2.5 equiv) glucose-6-phosphate, glucose-6-phosphate dehydrogenase (2 units/mL), 4 μM (0.1 




of the Pik TE domain to provide direct evidence for the strict stereospecificity of Pik TE 
(see Chapter III). 
 
Generation of hybrid TE PKS modules  
To investigate the role of the TE domain in engineered PKS modules, we 
generated a series of hybrid type I PKS modules by combining modules from the 
pikromycin (Pik), erythromycin (DEBS), and juvenimycin (Juv) biosynthetic pathways 
with each corresponding TE domain. The TE domains from these 3 related pathways 
generate macrolactones that vary in size from 12 to 16-membered rings and contain 
unique chemical functionality (Figure 2.2). By generating this suite of hybrid TE PKS 
modules, we were able to test both the ability of each TE domain to function in an 
engineered PKS module and also probe PKS modules with both natural and unnatural 
substrates to ascertain the intrinsic substrate flexibility of each TE domain for 
macrolactonization. The TE domains from the Pik17 and DEBS18 biosynthetic pathways 
have been cloned and expressed as excised domains previously. In both cases, the C-
terminus of the TE contained the natural stop codon from the corresponding module 
while the N-terminus contained a portion of the ACP-TE interdomain linker region. 
Regarding Pik TE, the length of the linker region included in the TE was originally 
determined17 empirically by optimizing the protein for in vitro activity. Furthermore, 
Figure 2.1 Proposed shunt pathways when macrocyclization is compromised. Release mechanisms 
of unnatural Pik chain elongation intermediates from PikAIII-TE and the subsequent degradative 
pathways when TE catalyzed cyclization is impaired. 
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fusing the optimized Pik TE downstream of the Pik Mod5 ACP domain to generate 
PikAIII-TE15 resulted in a hybrid module capable of producing 10-dml (6)12,13 from the 
Pik pentaketide 1.  
For generating the hybrid TE modules in this study, we followed a similar strategy 
for each TE domain by including the natural stop codon from the C-terminus of each 
respective module, and determined the optimal N-terminal boundary through sequence 
alignment with the previously optimized Pik TE (Figure 2.3). Pik Mod5 and DEBS Mod5 
have been previously constructed13,15,19 as hybrid fusion proteins with the Pik and DEBS 
TE domains, respectively, and were modified slightly in this study to include the full 
selection of the aforementioned TE domains. Pik Mod6, DEBS Mod6, Juv Mod6, and 
Juv Mod7 hybrids were generated by inserting a restriction site at the 3’ end of the 
Figure 2.2 The thioesterase domains utilized in this study and the macrolactones they produce. 
Figure 2.3 Sequence alignment of the Pik, DEBS, and Juv thioesterase domains. The Pik and DEBS 
TEs have been cloned and described previously. The N-terminal portion of the Juv TE domain was 
determined in this study by sequence alignment with Pik and DEBS.  Sequences were aligned using 
T-coffee
20
 and rendered with ESPript
21
 The stars denote the positions of residues in the catalytic triad. 
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alignment consensus for each antiSMASH22 annotated ACP domain to allow for the 
insertion of the respective non-native TE domains (Figure 2.4). Following the cloning of 
each hybrid, we next performed expression of each His6-tagged protein in the E. coli 
strain BAP123, resulting in the production of 13 new hybrid TE modules. A single pass 
purification scheme was chosen to minimize the length of time each protein was 
processed since previous work has shown the most reproducible in vitro activity is 
achieved with short purification times.24 Purification by Ni-NTA affinity chromatography 
provided each protein in yields (Table 2.1) and purities (Figure 2.5) sufficient for 
enzymatic analysis. Although the Juv Mod6 hybrids contained significant contaminating 
species within the purified protein fractions (lanes 13-16, Figure 2.5), previous work25 
had shown Juv Mod6 retains high catalytic efficiency as a cell-free lysate, thus 
alleviating our concern over the purity of these proteins.  
 
Role of the TE domain in engineered PKS modules 
With a library of hybrid TE PKS modules in hand, we set out to assess the 
substrate flexibility of each TE domain and examine the role of the TE in each 
engineered system. Using previously optimized in vitro conditions24, we initially tested 
Pik Mod5 (the native module for processing Pik pentaketide 1, DEBS Mod5, DEBS 
Mod6, and Juv Mod6 hybrid modules for the ability to generate 10-dml (6) using the Pik 
pentaketide 124 as a substrate. This initial scheme was chosen due to our access to the 
authentic standards for product formation, as each of these hybrid modules share the 
same domain composition, and thus should produce either 10-dml (6) or 3-keto-10-dml 
26. HPLC quantification of the reaction products answered two key questions: First, TE  
Figure 2.4 Determination of the post-ACP restriction site for incorporating non-native TE domains. The 
location (black arrow) was chosen from alignment of the antiSMASH
22
 annotated ACP domain regions 
(orange highlight) for each PKS module. Sequences were aligned using T-coffee
20
 and rendered with 
ESPript.
21





Figure 2.5 PAGE gel of hybrid TE PKS modules. NuPAGE® Bis-Tris Mini, MOPS running buffer, 
BenchMark™ Pre-stained Protein Ladder. Lanes: 1. Pik Mod5-DEBS TE (186 kDa), 2. Pik Mod5-Juv 
TE (186 kDa), 3. Pik Mod5-Pik TE (187 kDa), 4. Pik Mod6-DEBS TE (138 kDa), 5. Pik Mod6-Juv TE 
(139 kDa), 6. Pik Mod6-Pik TE (143 kDa), 7. DEBS Mod5-DEBS TE (186 kDa), 8. DEBS Mod5-Juv TE 
(187 kDa), 9. DEBS Mod5-Pik TE (188 kDa), 10. DEBS Mod6-DEBS TE (178 kDa), 11. DEBS Mod6-
Juv TE (178 kDa), 12. DEBS Mod6-Pik TE (179 kDa), 13. Juv Mod6 (165 kDa), 14. Juv Mod6-DEBS 
TE (187 kDa), 15. Juv Mod6-Juv TE (188 kDa), 16. Juv Mod6-Pik TE (189 kDa), 17. Juv Mod7-DEBS 
TE (186 kDa), 18. Juv Mod7-Juv TE(187 kDa), 19. Juv Mod7-PikTE (188 kDa).  
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domains from homologous type I PKS pathways can function in a combinatorial 
manner, and secondly, proper pairing of the TE domain to the incoming linear 
intermediate is critical for achieving productive catalysis. Indeed, even in reactions 
pairing all non-native core PKS domains, we achieved significant conversions to 10-dml 
(6) if the Pik TE was in place (Table 2.2). These results demonstrate that the KS-AT-
ACP and KR domains from non-cognate PKS modules in our system maintained a 
suitable level of catalytic function when the downstream TE domain is correctly matched 
to the incoming unnatural intermediate. This is evidenced by the 21, 17, 41, and 75% 
conversions from the reactions containing, DEBS Mod5-Pik TE, DEBS Mod6-Pik TE, 
Juv Mod6-Pik TE, Pik Mod5-Pik TE, respectively (Table 2.2). These results also indicate 
that the DEBS and Juv TE domains are poorly suited for generating 12-membered 
macrolactones as the percent conversions dropped rapidly for hybrid modules paired 
with these TE domains. Thus, we interpret these stark variations achievable through 
replacement of a single domain to indicate that the TE domain is acting as a key 
gatekeeper in engineered PKS reactions.  
Table 2.1 Yields from the Ni-NTA column purification of the hybrid TE PKS modules.  
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 In effort to further our TE gatekeeper findings, we next probed the hybrid TE 
modules with the Pik hexaketide 27 (see Chapter III for details) to determine the extent 
to which the modules could accept and process the hexaketide to a 14-membered 
macrolactone. LC-HRMS screening of reactions containing 2-nitrobenzyloxymethyl 
(NBOM) ether protected thiophenol activated hexaketide26 27 with our panel of PKS 
modules revealed that DEBS Mod6, Juv Mod6, and Pik Mod6 were able to generate 14-
membered macrolactones. A large scale reaction containing DEBS Mod6-DEBS TE 
provided sufficient quantities of 28 for structural characterization. HPLC quantification of 
the reaction products indicated that our panel of PKS modules followed a similar 
reactivity trend as with the pentaketide (Table 2.3). Consistent with our previous report26 
Pik Mod6 is able to efficiently process the Pik hexaketide to narbonolide (23), however 
Table 2.2 Screening of hybrid TE modules with Pik pentaketide. Enzymatic reaction conditions: 
sodium phosphate buffer (400 mM, pH = 7.2), 0.5 mM Pik pentaketide, 10 mM (20 equiv) MM-NAC, 4 
mM (8 equiv) 2-vinylpyridine, 0.25 mM (50 mol%) NADP
+
, 1.25 mM (2.5 equiv) glucose-6-phosphate, 
glucose-6-phosphate dehydrogenase (2 units/mL), 2 μM (0.4 mol %) PKS module, 4 hours, stationary, 
RT. Conversion to 6 (R1=OH, R2=H) or 26 (R1=R2=O) was monitored by HPLC with data represented 
as the mean ± standard deviation where n = 3. Trace=detected by LC-HRMS but below the detection 
limit of HPLC. ND= not detected. 
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substitution of the TE domain to either the DEBS or Juv TE causes a precipitous drop in 
conversions, which we interpret to indicate the DEBS and Juv TE domains require the 
C-3 reduced intermediate for cyclization (vide infra). DEBS Mod6 when paired with 
either the DEBS or Juv TE was able to process the hexaketide to 3-hydro-narbonolide 
28 at 34 and 9.6% conversions, respectively. However, DEBS Mod6-Pik TE produces 
predominantly the unreduced narbonolide (23), indicating that fusion with the Pik TE 
interferes with the native catalytic cycle. It is unclear at this time what the mechanism for 
this switch in product formation stems from. We note that the native Pik substrate is 
unreduced at the C-3 position and the Pik TE may have a higher binding affinity for the 
ACP-tethered intermediate prior to β-keto reduction thus leading to premature 
cyclization. Reactions containing Juv Mod6 with the DEBS and Pik TE yielded trace 
quantities of 23 and 28, respectively, indicating that Juv Mod6 does not efficiently 
Table 2.3 Evaluation of TE hybrids with Pik hexaketide. 27 is generated in situ by photolysis of the 2-
nitrobenzyloxymethyl ether (NBOM) protected native hexaketide
22
. Enzymatic reaction conditions: (*) 
sodium phosphate buffer (400 mM, pH = 7.2), 1 mM Pik hexaketide, 20 mM (20 equiv) MM-NAC, 8 
mM (8 equiv) 2-vinylpyridine, 1 mM sodium metabisulfite and 25 mM ascorbic acid (**) and 0.5 mM (50 
mol%) NADP
+
, 2.5 mM (2.5 equiv) glucose-6-phosphate, glucose-6-phosphate dehydrogenase (2 
units/mL), 2.5 μM (0.25 mol %) PKS module, 4 hours, stationary, RT. Conversion to 23 (R1=OH, R2=H) 
or 28 (R1=R2=O) was monitored by HPLC with data represented as the mean ± standard deviation 
where n = 3. Trace=detected by LC-HRMS but below the detection limit of HPLC. ND= not detected. 
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accept or process the Pik hexaketide. In contrast with the results from our reactions with 
1 (Table 2.2), DEBS TE retained a significant level of reactivity when generating the 14-
membered macrolactones. This is perhaps unsurprising as the native product from the 
DEBS PKS is the 14-membered 6-dEB (24, Figure 2.2) and the macrolactones 23 and 
28 are similar in both size and functionality. Of note, both the DEBS and Juv TEs 
appear to be sensitive to the identity of the functional group at the C-3 position and only 
are capable of effectively forming the 3-hydro-narbonolide 28 species which contains 
the same functionality as their native products at this position.   
Recently, the Sherman lab reported the cloning and in vitro activity of the 
penultimate (Juv Mod6) and terminal (Juv Mod7) modules from the Juvenimycin 
biosynthetic pathway which are homologous with the corresponding modules from the 
tylosin pathway but are more amenable to in vitro analysis.25 We were curious to test 
the ability of the hybrid TE strategy to mimic late stage PKS engineering by performing 
reactions requiring substrate processing by two PKS modules to understand if the 
hybrid TE modules retained viability for productive interaction with the upstream 
module. We thus expanded our investigations into TE substrate flexibility by analyzing 
Juv Mod7 TE hybrids paired with Juv Mod6 in conjunction with the Tyl hexaketide 29 
(Table 2.4). LC-HRMS analysis of the Juv Mod7 reactions revealed all three TE 
domains possessed the ability to generate the 16-membered macrolactone when fused 
to Juv Mod7. HPLC quantification of tylactone (25) production demonstrated Juv Mod7-
Juv TE to be the most efficient at 34% conversion, followed closely by Juv Mod7-DEBS 
TE at 30% conversion. Juv Mod7-Pik TE was significantly less adept at producing 
tylactone with levels below the detection limit of the HPLC assay. Notably this 
represents the first example of the DEBS and Pik TE domains producing a 16-
membered macrolactone in vitro27 and confirms that systems containing engineered TE 




Biocatalytic production of macrolactone analogs 
After identifying the TE as a crucial gatekeeper domain in the processing of 
unnatural substrates, we next sought to harness this information for the production of 
novel macrolactones. To accomplish this, we screened our library of hybrid PKS 
modules with the Tyl hexaketide 29 to probe each of them for the ability to generate a 
14-membered diene macrolactone. Analytical experiments assessed by LC-HRMS 
indicated reactions containing 29 with Juv Mod6-Pik TE successfully produced a new 
macrolactone product. To validate our analytical findings, we performed a 0.1 mmol 
scale reaction and purified the reaction products by preparatory reverse phase HPLC. 
Initial characterization of the purified reaction products by LC-HRMS (Figure 2.6) 
indicated that the scale-up reaction did successfully produce the 14-membered 
macrolactone 30 in a 12% yield (Scheme 2.3). We are currently performing a full 
structural characterization of the suspected macrolactone product using two-
dimensional nuclear magnetic resonance spectroscopy (2D-NMR) to confirm the mass 
Table 2.4 Reaction of Juv Mod7 hybrids with Tyl hexaketide 29. Enzymatic reaction conditions: 
sodium phosphate buffer (400 mM, pH = 7.2), 0.5 mM Tyl hexaketide, 10 mM (20 equiv) MM-NAC, 10 
mM (20 equiv) M-NAC, 4 mM (8 equiv) 2-vinylpyridine, 0.25 mM (50 mol%) NADP
+
, 1.25 mM (2.5 
equiv) glucose-6-phosphate, glucose-6-phosphate dehydrogenase (2 units/mL), 4 μM (0.8 mol %) 
PKS module, 4 hours, stationary, RT. Conversion to 25 was monitored by HPLC with data represented 
as the mean ± standard deviation where n = 3. Trace=detected by LC-HRMS but below the detection 




spectrometry results. The production of this macrolactone was of significant interest as 
we predicted the conjugated diene would produce a highly strained macrolactone ring 
structure. Furthermore this product was unobtainable through reactions containing 
native PKS modules, highlighting the power of TE domain engineering for producing 









Figure 2.6 LC-HRMS analysis of the purified product from reactions containing Juv Mod6-Pik TE with 
Tyl hexaketide 29. The observed molecular ion at m/z 351.2533 matches closely with the calculated 
value of m/z 351.2529. Full characterization of this molecule is currently in progress.  
Scheme 2.3 Reaction of Juv Mod6-Pik TE with Tyl hexaketide 29. Enzymatic reaction conditions: 
sodium phosphate buffer (400 mM, pH = 7.2), 0.5 mM Tyl hexaketide, 10 mM (20 equiv) MM-NAC, 
0.25 mM (50 mol%) NADP
+
, 1.25 mM (2.5 equiv) glucose-6-phosphate, glucose-6-phosphate 





Reactions were performed in evacuated (<0.05 torr) flame dried glassware backfilled 
with dry N2 and run under a positive pressure of dry N2 provided by a mineral oil bubbler 
unless stated otherwise (open flask). Reactions at elevated temperatures were 
controlled by IKA RET Control Visc (model RS 232 C), room temperature (RT) reactions 
were conducted at ~23 °C, reactions run cooler than room temperature were performed 
in ice (0 °C) or dry ice/acetone (-78 °C) baths. Analytical thin-layer chromatography 
(TLC) was performed with EMD 60 F254 pre-coated glass plates (0.25 mm) and 
visualized using a combination of UV, p-anisaldehyde, KMnO4, and bromocresol green 
stains. Flash column chromatography was performed using EMD 60 Gerduran® 
(particle size 0.04-0.063) silica gel. Commercial purification system MBraun-MB-SPS # 
08-113 provided all dry solvents unless stated otherwise (technical grade). NMR spectra 
were recorded on a Varian 600 MHz spectrometer. 1H NMR spectra were recorded 
relative to residual solvent peak (CDCl3 δH 7.26 ppm, D6-DMSO δH 2.50 ppm, D6-
acetone δc 2.05 ppm) and reported as follows: chemical shift (ppm), multiplicity, coupling 
constant (Hz), and integration. Multiplicity abbreviations are as follows: s = singlet, d = 
doublet, t = triplet, q = quartet, quint = quintet, h = hextet, ovlp = overlap, br = broad 
signal. 13C NMR spectra were recorded relative to residual solvent peaks (CDCl3 δC 
77.0 ppm, D6-DMSO δc 39.5 ppm, D6-acetone δc 29.8 ppm). High resolution mass 
spectrometry was performed on an Agilent quadrapole time-of-flight spectrometer (Q-
TOF 6500 series) by electrospray ionization (ESI). 
 
26: A 4-dram vial was charged with 626 (50 mg, 0.168 mmol, 1 equiv), technical grade 
DMSO (0.5 mL), IBX (0.09 g, 0.34 mmol, 2 equiv) was added and the reaction was 
placed in a water bath, and heated to 50 °C with stirring. The reaction was monitored by 
TLC, and after consumption of starting material (~3 h) the reaction mixture was 
concentrated under rotary high vacuum and purified directly. Flash chromatography: 




1H NMR (700 MHz; CD3OD): δ 6.88 (dd, J = 15.8, 5.3 Hz, 1H), 6.70 (dd, J = 15.8, 0.9 
Hz, 1H), 5.11 (ddd, J = 8.7, 5.1, 2.2 Hz, 1H), 3.87 – 3.82 (m, 1H), 3.35 – 3.32 (m, 1H), 
2.84 – 2.79 (m, 1H), 2.62 – 2.56 (m, 1H), 2.41 (dqd, J = 12.8, 6.4, 1.9 Hz, 1H), 2.20 – 
2.14 (m, 1H), 1.82 – 1.75 (m, 1H), 1.72 – 1.63 (m, 2H), 1.29 (d, J = 7.0 Hz, 3H), 1.26 (d, 
J = 7.0 Hz, 3H), 1.22 (d, J = 6.9 Hz, 3H), 0.99 (d, J = 6.4 Hz, 3H), 0.96 (t, J = 7.4 Hz, 
3H). 
13C NMR (700 MHz; CD3OD): δ 208.5, 206.5, 174.5, 150.0, 127.0, 77.1, 50.7, 46.9, 
43.0, 39.8, 38.8, 26.2, 17.31, 14.0, 13.7, 10.7, 9.7. 
HRMS: Calculated [M+Na]+ 317.1723, found 317.1727. 
 
Cloning of hybrid PKS modules 
The cloning, expression, and purification of Pik Mod528, Pik Mod5-PikTE15, Pik Mod628, 
Pik TE17, DEBS Mod513, DEBS Mod5-DEBS TE13, DEBS Mod613, DEBS TE18, Juv 
Mod625, and Juv Mod725 have been previously reported.   
 
The hybrid TE proteins utilized in this study were generated by the following 
procedures: 
The Juv TE domain region was determined by sequence alignment to Pik and DEBS 
and PCR amplified from pET21-Juv Mod7  using primers 5’-
ccaaccgaattcaccggcgcggcgggcgggccacc-3’ and 5’-
ccaaccctcgagtcatgcggccgcaagcttcggaacgcg-3’ and subsequently inserted into pET28b 
using EcoRI and XhoI. This construct was then used as the template for two rounds of 
mutagenesis following the QuikChange site-directed mutagenesis (Stratagene) protocol  
to remove an internal BamHI site using primers 5’- ggggcctggccggacccccggcaggactg-3’ 
and 5’-cagtcctgccgggggtccggccaggcccc-3’, and HindIII site using primers 5’-
gtgcggccgcaagtttcggaacgcgag-3’ and 5’-cgcctggcggtaccggatcgcctggc-3’. This modified 






Pik Mod5-TE hybrids: 
pET24b Pik Mod5-Pik TE15 was digested with HindIII and XhoI to allow for fusion with 
the DEBS TE using primers 5’-ccaaccaagcttagcgggactcccgcccgggaagcg-3’ and 5’-




Pik Mod6–TE hybrids: 
The Pik Mod6-TE hybrids were constructed from pET24b Pik Mod628 in two steps. First, 
Pik Mod6 was truncated at the 3’ end to its corresponding ACP domain by digestion 
with EcoRI and HindIII followed by ligation with a similarly digested PCR amplification 
product generated using primers 5’-gacagctcacccgaattc-3’ and 5’-
ccaaccaagcttcagctcgtcgctgatgcgctcggc-3’. Next this intermediate was digested with 
HindIII and XhoI to allow for fusion with the DEBS TE using primers 5’-
ccaaccaagcttagcgggactcccgcccgggaagcg-3’ and 5’-




DEBS Mod5-TE hybrids:   
pET28b DEBS Mod5-DEBS TE13 was digested with BamHI and XhoI to allow for fusion 
with Pik TE using primers 5’-ccaaccggatcctccggggccgacaccggc-3’ and 5’-
ccttccctcgagtcagcccgccccctcgatgcc-3’, DEBS TE using primers 5’-
ccaaccggatccagcgggactcccgcccgggaagcg-3’ and 5’-








DEBS Mod6-TE hybrids: 
The DEBS Mod6-TE hybrids were constructed from pET24b DEBS Mod613 in two steps. 
First, DEBS Mod6 was truncated at the 3’ end to its corresponding ACP domain by 
digestion with XbaI and EcoRI followed by ligation with a similarly digested PCR 
amplification product generated  using primers 5’-cccctctagaaataattttgtttaactttaagaagg-
3’ and 5’-ccaaccgaattcgagctgctgtcctatgtggtcg-3’. Next this intermediate was digested 
with EcoRI and  HindIII to allow for fusion with the Pik TE using primers 5’-
ccaaccgaattctccggggccgacaccggc-3’ and 5’-ccaaccaagcttgcccgccccctcgatgcc-3’, and 
the Juv TE using primers 5’-ccaaccgaattcaccggcgcggcgggcgggccacc-3’ and 5’-
ccaaccaagctttgcggccgcaagcttcggaacgcg-3’.  
 
Juv Mod6-TE hybrids: 
The Juv Mod6-TE hybrids were constructed from pET28b Juv Mod625 in two steps. 
First, Juv Mod6 was truncated at the 3’ end to its corresponding ACP domain by 
digestion with NdeI and HindIII followed by ligation with a similarly digested PCR 
amplification product generated using primers 5’- ccaacccatatgtcgaacgagcagaagctccgc-
3’ and 5’- ccaaccaagcttgagcagcccggccaggtgctcggc-3’. Next this intermediate was 
digested with HindIII and XhoI to allow for fusion with the Pik TE using primers 5’- 
ccaaccaagctttccggggccgacaccggc-3’ and 5’- ccaaccctcgagtcacttgcccgccccctcga-3’, the 
DEBS TE using primers 5’- ccaaccaagcttagcgggactcccgcccgggaagcg-3’ and 5’- 
ccaaccctcgagtcatgaattccctccgcccagccaggc-3’, and the Juv TE using primers 5’- 
ccaaccaagcttaccggcgcggcgggcgggccaacc-3’ and 5’- 
ccaaccctcgagtcatgcggccgcaagcttcggaacgcg-3’.  
 
Juv Mod7-TE hybrids: 
The Juv Mod7-TE hybrids were constructed from pET21b Juv Mod725 in two steps. 
First, Juv Mod7 was truncated at the 3’ end to its corresponding ACP domain by 
digestion with KpnI and HindIII followed by ligation with a similarly digested PCR 
amplification product generated using primers 5’- cgcctggcggtaccggatcgcctggc-3’ and 
5’- ccaaccaagcttgagcaggccgtgcaggtgcgcggc-3’. Next this intermediate was digested 
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with HindIII and XhoI to allow for fusion with the Pik TE using primers 5’- 
ccaaccaagctttccggggccgacaccggc-3’ and 5’- ccaaccctcgagcttgcccgccccctcga-3’, and the 




Cell culture, protein purification, and enzymatic reactions were performed using water 
obtained from a Millipore Milli-Q system with Millipore Q-Gard 2/Quantum Ex Ultrapure 
organex cartridges. E. coli culture growth was performed in 15 mL sterile tubes for the 
seed cultures and 2.8 L Corning Fernbach flasks with deep baffles (3x) for protein 
expression cultures. Reagents were obtained from the following sources: LB broth 
(Miller) and glycerol were obtained from EMD. Isopropyl-β-D-thiogalactopyranoside 
(IPTG), Kanamycin sulfate (Kan), and Ampicillin (Amp) were obtained from Gold 
Biotechnology. NaCl, CaCl2 and imidazole were obtained from Fisher Scientific. 
Lysozyme was purchased from RPI, PD-10 columns were purchased from GE scientific, 
and Ni-NTA agarose resin was purchased from Qiagen. The pH of all solutions was 
monitored via a Symphony SB70P pH meter calibrated according to the manufacturer’s 
specifications. Optical density (OD600) was determined using an Eppendorf 
Biophotometer and cell lysis was accomplished using a 550 Sonic Dismembrator 
purchased from Fisher Scientific. All solutions were autoclaved or sterile filtered (0.2 
µm) prior to use.  
 
Buffers: 
 lysis: HEPES (50 mM), NaCl (300 mM), imidazole (10 mM), glycerol (10% v/v), pH 8.0.  
wash: HEPES (50 mM), NaCl (300 mM), imidazole (30 mM), glycerol (10% v/v), pH 8.0.  
elution: HEPES (50 mM), NaCl (300 mM), imidazole (300 mM), glycerol (10% v/v), pH 
8.0.  







A starter culture was generated by inoculating 5 mL of LB broth containing Kan or Amp 
(50 mg/L) with fresh transformants of E. coli (BAP1)23 cells containing the corresponding 
plasmids for expression of the respective PKS proteins and grown overnight at 37 ˚C. 
Following the overnight growth, the entire starter culture was subsequently used to 
inoculate an expression culture of 1 L of TB containing Kan or Amp (50 mg/L) and 
grown at 37 ˚C to an OD600 of 0.3-0.4. The expression cultures were then cooled to 18 
˚C and growth was maintained until an OD600 of 0.7-0.8 was reached, at which point 
protein expression was induced via addition of IPTG (350 µM) and the cultures were 
incubated at 200 RPM at 18 ˚C for 20 hours.  
 
Protein purification 
Protein expression cultures were cooled to 4 ˚C and harvested by centrifugation (6,500 
x g, 10 min, 4 ˚C). The pelleted cells were then suspended in 5 mL of lysis buffer per 
gram of cells via vortex. Cell lysis was accomplished by the addition of 0.4 mg/mL 
lysozyme and the solution was then sonicated on ice (100 x 3s with 10s rest periods). 
The resulting cellular lysate was then pelleted by centrifugation (60,000 x g, 30 min, 4 
˚C) and the supernatant was applied to 6 mL of pre-equilibrated Ni-NTA resin. After 
binding, the column was washed with 15 column volumes of wash buffer and the target 
protein was subsequently eluted with 4 column volumes of elution buffer. Elution 
fractions were determined by their absorption at 280 nm, pooled, and buffer exchanged 
into storage buffer using a pre-equilibrated PD-10 column. After buffer exchange, the 
elution fractions were once again monitored via their absorption at 280 nm, pooled, 
flash frozen in liquid N2, and stored at -80 ˚C. 
 
Analytical enzymatic reactions  
All analytical scale reactions were performed in triplicate at a volume of 50 μL and 
quenched with 3 volumes of MeOH (150 μL), clarified by centrifugation (17,000 x g, 30 
min, 4 ˚C) and analyzed for product formation by HPLC. 2-vinylpyridine (Sigma) was 
employed as a thiol scavenger. Enzymatic reactions utilizing NBOM protected 
substrates were performed over two steps. First, a solution of ascorbic acid (25 mM final 
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concentration), sodium metabisulfite (1 mM final concentration), NBOM protected 
substrate (1 mM final concentration), and H2O (requisite dead volume) was irradiated 
under a consumer facial tanning lamp at a height of 14 cm (Verseo #AH129c) for 20 min 
to furnish the deprotected Pik hexaketide. NOTE: Irradiation through the side of the 
microtubes employed (Axygen #MCT-175-C) did not interfere with photolysis, and this 
process was reproducible over the course of this study. After photolysis, the solution 




Macrolactone production was monitored via analytical high performance liquid 
chromatography (HPLC) using a Shimadzu LC-20AD.  
Product formation in Table 2.2 was quantified using Phenomenex Luna 5μ C18 250 x 
4.6 mm column (serial 466013-1) monitoring at a wavelength of 236 nm. Separation 
was accomplished by the following method: 1.5 mL/min, solvent A: H2O 0.1% formic 
acid, solvent B: MeCN 0.1% formic acid, 5% B 0-1 min, 5-100% B linear gradient 1-12 
min, 100% B 12-15 min, 5% B 15-17.5 min.  
 
Product formation in Table 2.3 and 2.4 was quantified using a Zorbax SB-Phenyl 3.5 μM 
4.6 x 150 mm column (part number 863953-912) monitoring at a wavelength of 236 nm. 
Separation was accomplished by the following method: 3.0 mL/min, solvent A: H2O 
0.1% formic acid, solvent B: MeCN 0.1% formic acid, 5% B 0-1 min, 5-70% B linear 
gradient 1-13 min, 100% B 13-15 min, 5% B 15-17 min. 
 
LC-HRMS analysis:  
Analytical liquid chromatography-mass spectrometry (LC-MS) was performed on an 
Agilent LC system (1290 series) coupled to an Agilent QTOF mass spectrometer (6500 
series) using a Phenomenex Synergi 4μ Hydro RP 100 x 2 mm column (serial 48836-5) 
heated to 50 °C. Method: 0.4 mL/min, solvent A: H2O 0.1% formic acid, solvent B: 
MeCN 0.1% formic acid, 0% B 0-2 min,0-100% B linear gradient 2-10 min, 100% 10-11 
min, 0% B 11-12 min, 0-1 min were diverted to waste.  
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Large scale reactions for product characterization 
Incubation of 27 with DEBS Mod6-DEBS TE: 
Reaction conditions: sodium phosphate buffer (400 mM, 20% v/v glycerol, 92 mL total, 
pH = 7.2), hexaketide 27 (51 mg, 0.09 mmol, 1 mM), MM-SNAC (20 equiv, 20 mM), 
NADP+ (0.5 equiv, 0.5 mM), glucose-6-phosphate (2.5 equiv, 2.5 mM), glucose-6-
phosphate dehydrogenase (2 units/mL), 2-vinylpyridine (8 mM), ascorbic acid (25 mM), 
sodium metabisulfite (1 mM), DEBS Mod6 (1 μM, 0.1 mol%), 20 hours, stationary, RT.  
 
Workup and purification:  Quenched with acetone (2x volume, 184 mL), placed in a -20 
°C freezer for 1 hour and filtered through a celite plug.  Remaining insoluble material 
was suspended in acetone and this solution was used to rinse the celite plug.  Acetone 
was removed through rotary evaporation and the aqueous layer was saturated with 
NaCl and extracted 3x EtOAc. Combined organic layers were concentrated. 30 was 
purified directly by preparatory HPLC using a Phenomenex Luna 5u C18 250 x 21.2 mm 
column (serial 444304-4) monitoring at 250 nM. Method 9 mL/min, A: H2O 0.1% formic 
acid, B: MeCN 0.1% formic acid, 5% B 0-5 min, 5-100% B linear gradient 5-45 min, 
100% B 45-65 min, 5% 65-75 min. 
 
28 from Pik hexaketide 27 (4.1 mg, 0.089 mmol, 12.6% yield). 
1H NMR (700 MHz, cd3od) δ 7.11 (dd, J = 15.9, 4.5 Hz, 1H), 6.27 (dd, J = 15.9, 2.0 Hz, 
1H), 5.10 (ddd, J = 9.4, 4.5, 1.8 Hz, 1H), 3.44 (dd, J = 9.0, 1.5 Hz, 1H), 3.41 (dd, J = 
7.2, 1.3 Hz, 1H), 2.69 (ddd, J = 8.7, 4.3, 2.0 Hz, 1H), 2.63 (ddd, J = 10.8, 7.0, 4.0 Hz, 
1H), 2.55 (m, 1H), 1.78 (m, 1H), 1.76 (ddd, J = 14.1, 7.0, 4.9 Hz, 1H), 1.63 (ddd, J = 
14.0, 7.4, 4.6 Hz, 1H), 1.41 – 1.35 (m, 1H), 1.31 – 1.26 (m, 1H), 1.25 (s, 1H), 1.22 (d, J 
= 4.0 Hz, 1H), 1.20 (t, J = 4.4 Hz, 1H), 1.18 (d, J = 6.9 Hz, 3H), 1.15 (d, J = 6.9 Hz, 3H), 
1.13 (d, J = 6.8 Hz, 3H), 1.03 (d, J = 6.7 Hz, 3H), 0.95 (m, 3H), 0.93 (d, J = 7.4 Hz, 2H). 
13C NMR (700 MHz; CD3OD) δ 206.07, 177.72, 152.84, 124.72, 78.40, 78.10, 75.00, 
45.90, 45.30, 42.93, 40.80, 37.45, 35.71, 26.52, 19.41, 18.03, 15.61, 10.92, 10.34, 8.92. 





Incubation of 29 with Juv Mod6-Pik TE: 
Reaction conditions: sodium phosphate buffer (400 mM, 20% v/v glycerol, 205 mL total, 
pH = 7.2), hexaketide 31 (42 mg, 0.1 mmol, 0.5 mM), MM-SNAC (20 equiv, 10 mM), 
NADP+ (0.5 equiv, 0.25 mM), glucose-6-phosphate (2.5 equiv, 1.25 mM), glucose-6-
phosphate dehydrogenase (2 units/mL), Juv Mod6-Pik TE (4 μM, 0.8 mol%), 20 hours, 
stationary, RT.  
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Introduction    
Macrocycles are a common motif amongst natural product and natural product 
derived therapeutics, with >100 marketed drugs possessing a macrocyclic core.1 The 
conformational preorganization of these large rings enables precise display of their 
functional groups to engage challenging targets such as protein-protein interactions, 
and, in the case of macrolides, ribosomal machinery.2-4 The macrolactone core of 
macrolide5 natural products is formed through two steps: first, the linear intermediate is 
transferred from the upstream acyl carrier protein (ACP) to a catalytic serine of the TE 
via a transesterification to form an acyl-enzyme complex. Next, the acyl intermediate is 
offloaded via intermolecular water hydrolysis or intramolecular nucleophilic attack to 
release the product as a linear acid or macrolactone, respectively6 (Figure 3.1). The 
macrolactonization of natural product analogs is notoriously difficult  to perform 
synthetically7 and formation of the macrocycle is a key feature of many bioactive 
polyketide and nonribosomal peptide natural products.8 Thus, we were intrigued by the 
prospect that the TE domain is serving as a gatekeeper domain in engineered PKS 
pathways.  
Biochemical and structural studies of the Pik TE and related DEBS TE 
(erythromycin pathway) have provided initial insights into the mechanism of ring 
formation over hydrolysis.9,10 While it is generally accepted that modular type I TE 
domains have high substrate flexibility for the initial acylation step, the second, 
macrolactone forming release step is far more stringent.6 Since the formation of the 
macrocyclic core is essential for downstream tailoring and biological activity of a natural 
product, aberrant hydrolysis limits access to new macrocyclic analogs. In vivo 
Figure 3.1 TE catalyzed macrolactonization or hydrolysis of an ACP-tethered polyketide intermediate. 
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engineering of the DEBS biosynthetic pathway has shown that DEBS TE possesses 
some tolerance to modifications in both the length and functionality of the linear 
polyketide substrate. Modifications in the DEBS pathway have yielded a large number 
of 6-dEB analogs from differential extender unit incorporation and reductive 
processing11-18 as well as macrolactones ranging in size from 6- to 16-membered 
rings.19-22 However, the titers of these unnatural products are greatly diminished 
compared to wild type production levels6, and the inherent complexity of in vivo 
biosynthesis has prevented identification of pathway bottlenecks, such as TE domains.  
Initial in vitro biochemical characterization of the DEBS TE23,24 provided further 
evidence for the relatively high substrate tolerance of PKS TEs for acylation and 
hydrolysis, as terminally (omega) hydroxylated fatty acids and substrates resembling 
simplified DEBS heptaketides were all hydrolyzed by DEBS TE. However, the ability of 
PKS TEs to cyclize substrates other than their native linear intermediates has proved to 
be much more limited. In fact, TE mediated macrolactonization has only been observed 
in a select few studies.25-34 
In addition to its native substrate, DEBS TE has been shown to catalyze 
macrolactonization of unnatural mimics of the DEBS heptaketide.30,33 However, there 
are no reports of either the Pik or DEBS TEs catalyzing macrolactonization of a 
substrate containing a nucleophilic hydroxyl group with an unnatural, epimerized (S)-
configuration. When probed for the ability to form an epimeric heptaketide mimic of 6-
dEB , the DEBS TE displayed a high level of stereoselectivity for the natural (R)-
configuration, and exclusively hydrolyzed the unnatural (S)-stereoisomer33, adding to 
the observations in Chapter II indicating strict stereospecificity in TE catalyzed 
macrolactonization. 
 
Stabilization of the Pik hexaketide 
To further our understanding of the TE domain in the processing of unnatural 
substrates, we next set out to investigate the mechanistic parameters that govern 
macrolactonization directly by probing the TE as an excised domain.34 However, the 
previously observed instability of the Pik TE native substrate (Pik hexaketide 4) imposes 
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considerable experimental challenges35,36, and required a practical solution prior to 
downstream study (Figure 3.2). While mature natural products typically possess 
adequate stability to survive isolation and purification from natural sources, polyketide 
intermediates often degrade rapidly through intramolecular hemiketalization and 
dehydration pathways presenting experimental bottlenecks in terms of synthetic 
accessibility and limited shelf-life.35-38 Although the structural basis remains unclear, 
polyketide elongation intermediates that are covalently attached to the ACP domain 
during biosynthesis are likely stabilized through sequestration within the PKS 
polypeptide scaffold.39,40 
Thus, to protect the pikromycin hexaketide for enhanced stability to enable 
downstream biochemical studies, we considered two distinct stabilization strategies: (i) 
a sterically undemanding protecting group that would remain attached throughout the 
catalytic cycle, and (ii) a protecting group that could be removed in a controlled manner 
to provide the native hexaketide immediately before use in enzymatic reactions. The 
corresponding seco-acids were produced starting from 10-dml (5) acquired by 
fermentation of an engineered strain of Streptomyces venezuelae ATCC 15439. 
Ultimately, a methyl ether protecting group was chosen to satisfy (i) and a 
photocleavable 2-nitrobenzyloxymethyl ether moiety (NBOM)41 was explored to address 
objective (ii) (see reference 34 for synthetic details ).   
Figure 3.2 Examples of previously studied native PKS chain elongation intermediates. Hydroxyl 




 With C-3 protected hexaketides in hand, we next analyzed the ability of Pik TE to 
generate 10-dml (5) and methyl protected 10-dml 9 from NBOM protected thiophenol 
hexaketide 7 and methyl protected thiophenol hexaketide 8, respectively. Initial reaction 
schemes were chosen based on previous work from Hansen et al. using thiophenol 
thioesters to load the substrate onto the PKS machinery in vitro.42 HPLC quantification 
of  reaction products using synthetic standards revealed that the in vitro reactions were 
sluggish resulting in conversions of 36% to 5 and only 10% to C-3 methyl protected 9 
(Scheme 3.1), prompting further investigations into substrate optimization. 
 
Substrate controlled divergence in polyketide synthase catalysis 
In order to study isolated PKS TE domains in vitro, investigations have relied 
upon electrophilic thioesters for diffusive loading in lieu of transfer from an upstream 
ACP. Historically, N-acetylcysteamine43,44 (NAC) has been the thioester of choice as it 
mimics the terminal portion of the phosphopantetheine arm that tethers a growing 
polyketide chain.45 In vitro studies of PikAIV with its native substrate have highlighted a 
key observation: Specifically, when incubated directly with N-acetylcysteamine Pik 
hexaketide 446 PikAIV afforded a 4:1 ratio of macrolactones 10-dml (5) and narbonolide 
(10).46 However, reaction schemes pairing PikAIII/PikAIV35,47 with Pik pentaketide 1 
where PikAIII performs an extension and delivers the hexaketide to PikAIV via an ACP5 
Scheme 3.1 Probing the Pik TE as an excised domain. Reactions containing Pik TE and the 
thiophenol thioester C-3 methyl and NBOM protected hexaketides 7 and 8 result in the production of 




thioester favor narbonolide as the major product (Figure 3.3).  Additionally, optimization 
of PikAIII (as an unnatural TE fusion48 or when paired with the final module, PikAIV) 
demonstrated improved catalysis with thiophenol thioesters49 over N-acetylcysteamine 
thioesters.35 These results suggest that the choice of thioester employed by the 
substrate largely determines the enzymatic domain(s) that will be efficiently acylated 
within a PKS assembly line. Thus, we hypothesized the lower than expected 
conversions reported in Scheme 3.1 were due in part to suboptimal thioester usage and 
motivated us to further explore substrate engineering approaches for in vitro reactions 
with Pik TE.   
 Starting with the C-3 protected seco-acids, we synthesized a series of 
hexaketides with a variety of thio- and oxoesters (see reference 28 for synthetic details) 
to test for loading onto Pik TE (Table 3.1).  For NBOM protected substrates, 4-
nitrophenol (entry 6) and N-hydroxysuccinimide (entry 8) substrates decomposed 
Figure 3.3 Product distributions from previous in vitro analysis of PikAIV. (a) Direct incubation of 
PikAIV with the N-acetylcysteamine thioester of the Pik hexaketide 4 results primarily in direct 
cyclization to 12-membered ring 10-dml. (b)  Reaction schemes using the Pik pentaketide and PikAIII 
to present the hexaketide intermediate as an acyl-ACP result primarily in full-module processing to 14-




rapidly upon photolysis and subsequently gave low conversion to macrolactones. In 
contrast, the corresponding hexaketide thiophenol, benzyl mercaptan and N-
acetylcysteamine thioesters photolyzed smoothly (entries 2, 4, and 10, respectively), 
with N-acetylcysteamine yielding the highest level of conversion to 10-dml (5). The 
methyl protected substrates followed a similar trend; however, the overall conversions 
were decreased in comparison to the photolyzed substrates, indicating the methyl ether 
protecting group negatively effects macrolactonization to a small extent. These 
experiments demonstrated the significant variation in macrolactonization efficiency to 
10-dml (5) or methyl 10-dml 9 dictated by the ester employed. N-acetylcysteamine 
thioester (entries 9-10) gave the highest conversion to 10-dml (5) or methyl protected 
10-dml (9) under all conditions tested, with N-hydoxysuccinimide esters providing 
moderate conversion to methyl protected 10-dml (9) (entry 7). These results indicate 
Table 3.1 Evaluation of stabilized Pik hexaketides with Pik TE. Enzymatic reaction conditions: 1 mM 
Pik hexaketide, 8 mM 2-vinylpyridine, 1 mM sodium metabisulfite and 25 mM ascorbic acid with 
NBOM photolysis, 1 mol% Pik TE (10 μM), 4 hours, RT. Conversion to 5 (R3 = H) or 9 (R3 = Me) was 
monitored (HPLC) with data represented as the mean ± standard deviation where n = 3. 
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that thiophenol thioesters are inefficient for direct macrolactonization utilizing the 
excised TE domain, and highlight the crucial nature of substrate optimization when 
studying PKS enyzmes in vitro. Surprisingly, a series of control reactions were 
conducted with NBOM protected hexaketides and Pik TE without photolysis, and 
yielded appreciable conversions to NBOM protected 10-dml 11 (Table 3.2). The same 
general trends were observed with N-acetylcysteamine giving the highest levels of 
conversion, followed by N-hydroxysuccinimide, with aryl and benzyl thio- and oxoesters 
giving uniformly low levels of product formation.   
 After observing the stark variations in TE catalysis with hexaketides bearing 
different thio- and oxoesters, we next pursued experiments utilizing this substrate panel 
Table 3.2 Evaluation of NBOM protected Pik hexaketides without photolysis. Enzymatic reaction 
conditions: 1 mM Pik hexaketide, 8 mM 2-vinylpyridine, 1 mol% Pik TE (10 µM), 4 hours, RT. 
Conversion to 11 was monitored (HPLC) with data represented as the mean ± standard deviation 




with the terminal module PikAIV to determine if the variable conversions remained in the 
context of full module catalysis. To accomplish this, we performed a series of in vitro 
reactions containing PikAIV paired with the Pik hexaketide and methylmalonyl N-
acetylcysteamine (MM-NAC)49,50 as the extender unit (Table 3.3). Again, NBOM 
protected substrates, 4-nitrophenol (entry 6) and N-hydroxysuccinimide (entry 8) 
substrates decomposed rapidly upon photolysis and subsequently gave low conversion 
to macrolactones. In contrast, the corresponding hexaketide thiophenol, benzyl 
mercaptan and N-acetylcysteamine thioesters photolyzed smoothly (entries 2, 4, and 
10, respectively) though benzyl mercaptan thioesters (entry 4) gave lower overall 
conversion to either macrolactone. Remarkably, we observed significant selectivity in 
product formation depending on the type of ester employed, where the hexaketide 
thiophenol thioester (entry 2) demonstrated greater than 10:1 selectivity for generating 
narbonolide (10), while the hexaketide N-acetylcysteamine thioester (entry 10) showed 
greater than 10:1 selectivity for 10-dml (5) production. In parallel experiments 
methylated substrates were converted to methyl protected 10-dml (9) or methyl 
protected narbonolide (12) albeit with selectivity shifted toward methyl 10-dml (9) and 
reduced overall conversions relative to native the substrates generated through initial 
NBOM photolysis.    
The work described herein provides further insight into substrate loading 
parameters in modular PKS catalysis using thiophenol thioesters49, indicating that 
product formation can be influenced by the type of substrate ester employed.  While 
reactions with the native, upstream acyl-ACP likely offer the highest level of biosynthetic 
fidelity through docking domain mediated chain transfer51, thiophenol thioesters appear 
to be highly effective for achieving full module catalysis. We propose that substrate 
control can be explained, at least in part, through the observation that thiophenol 
thioesters suffer diminished conversion when incubated with the excised Pik TE domain 
(entries 1 and 2, Table 3.1) relative to the corresponding NAC thioesters (entries 9 and 
10, Table 3.1). Moreover, we36 and others23,52 have shown previously that PKS TE 
domains function as flexible hydrolases when substrate macrolactonization cannot be 
achieved. PikAIV is unique among terminal PKS modules as the TE domain is able to 
form both 12- and 14-membered rings. However, the likely result of errant TE acylation 
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in typical PKS modules is substrate hydrolysis and decreased conversion to the desired 
macrocyclic product, which greatly limits the effectiveness of PKS modules as 
biocatalysts. As such, optimizing PKS substrates through substrate engineering may 
minimize hydrolysis and other undesired side reactions.  
 In summary, the results with PikAIV and Pik TE clearly demonstrate the critical 
importance of substrate engineering as a tool for studying PKS enzymes in vitro. Methyl 
ether and NBOM mediated stabilization proved to be a viable strategy for reactions with 
the excised Pik TE. Additionally, the NBOM protecting group proved to effectively 
stabilize the Pik hexaketide prior to in vitro reactions and should offer ready stabilization 
of a range of advanced polyketide chain elongation substrates for PKS functional 
Table 3.3 Evaluation of stabilized Pik hexaketides with PikAIV and MM-NAC extender unit. Enzymatic 
reaction conditions: 1 mM Pik hexaketide, 20 mM MM-NAC, 8 mM 2-vinylpyridine, 1 mM sodium 
metabisulfite and 25 mM ascorbic acid with NBOM photolysis, 0.25 mol% PikAIV (2.5 μM), 4 hours, 
RT. Conversion to 5 (R3 = H) or 9 (R3 = Me) and 10 (R3 = H) or 12 (R3 = Me) was monitored (HPLC) 
with data represented as the mean ± standard deviation where n = 3. Trace=detected by LC-HRMS 




studies.  Moreover, its ability to undergo rapid and efficient photo-induced deprotection 
demonstrates its role as an effective tool for in vitro studies of PKS enzymes. 
 
Confirmation of a thioesterase bottleneck in the processing of unnatural 
substrates 
 With optimized in vitro conditions for probing the excised TE domain directly, we 
next performed experiments to directly confirm the TE bottleneck identified in Chapter II.  
To accomplish this, we began by synthesizing the N-acetylcysteamine thioester of the 
C-11-epimerized hexaketide, which is analogous to the C-9-epimerized pentaketide 
which failed to be processed by PikAIII-TE in Chapter II (see reference 47 for synthetic 
details), for probing the TE domain substrate stereospecificity directly.  With C-11-
epimerized methyl ether hexaketide 14 in hand, we next evaluated the ability of Pik TE 
to catalyze the macrolactonization of 14 to the corresponding epimeric macrolactone. 
HPLC analysis of analytical reactions containing the epimerized 14 resulted in complete 
hydrolysis to 15, and failed to produce any macrocylic product (Scheme 3.2). The 
exclusive hydrolysis of epimerized 14 confirms the TE domain as the dominant catalytic 
bottleneck in the processing of diastereomeric pentaketides observed in Chapter II. 
Scheme 3.2 Pik TE displays a high level of substrate stereospecificity. Enzymatic reaction conditions: 
sodium phosphate buffer (400 mM, pH 7.2), 1 mM hexaketide, 8 mM 2-vinylpyridine, purified Pik TE 
(10 μM), 4 hours, stationary, RT. Conversion 9 and 15 was monitored (HPLC) with data represented 




A single active site mutation in the pikromycin thioesterase generates a more 
effective macrocyclization catalyst 
After confirming Pik TE as the catalytic bottleneck in our engineered PKS 
modules from Chapter II, we next sought to engineer the TE domain for increased 
substrate flexibility, and the ability to generate diastereomeric macrolactones. We first 
desired to increase the efficiency of TE domain loading using 4-nitrophenyl substrates 
as the release of 4-nitrophenol from these reactions provides a spectrophotometric 
handle that is useful in directed evolution engineering methods.54 We expected that the 
KS over TE bias observed with thio- and oxoesters other than N-acetylcysteamine 
(entries 2 and 6, Table 3.3) was due in part to the cysteine active site nucleophile of the 
KS domain vs the corresponding serine nucleophile of the TE domain. Due to 
differences in atomic radii, electronegativity, and polarizability, sulfur atoms are 
significantly more nucleophilic than their oxygen congeners.55  Because of the larger 
size of the atom, non-bonding electron-pairs on sulfur are softer (more polarizable) than 
those on oxygen and consequently, electron-pairs on sulfur are better nucleophiles. 
Therefore, we reasoned that substitution of the WT Pik TE nucleophile serine 148 to an 
analogous cysteine would increase the relative nucleophilicity of the protein and 
subsequently lead to increased acylation.  
The cysteine mutant of Pik TE was generated from a pET28 plasmid encoding 
wild-type Pik TE by substitution of the wild type codon 148 TCC to TGT using the 
QuikChange site-directed mutagenesis (Stratagene) protocol. Expression and 
purification of Pik TES148C provided soluble protein in yields comparable to Pik TEWT. A 
single time point assay comparing Pik TEWT and TES148C provided a surprising result:  
Not only did Pik TES148C benefit from increased acylation with 4-nitrophenol esters, 
incubation with thiophenol and N-acetylcysteamine substrates also resulted in increased 
yields vs the WT enzyme (Figure 3.4). Encouraged by these initial results, we further 
investigated the catalytic performance of the S148C mutant by performing a reaction 
containing Pik TES148C with the epimerized 14. Remarkably, Pik TES148C was able to 
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efficiently cyclize 14 to the corresponding epimerized macrolactone 11-epi-10-dml 16 
(Scheme 3.3).  
In addition to the gain-of-function macrolactonization of 14, we also examined the 
kinetic effect of the S148C mutation on cyclization (Table 3.4). Steady state kinetic 
analysis of Pik TEWT and TES148C  was performed using both methyl protected Pik 
hexaketides 13 and 14, as well as NBOM protected34 native hexaketide 4, following a 
Figure 3.4 A single active site mutation in the pikromycin thioesterase generates a more effective 
macrocyclization catalyst. HPLC analysis of a single time point reaction demonstrates the stark 
catalytic advantage obtained with the S148C mutation (top) Evaluation of methyl protected Pik 
hexaketides with Pik TES148C (bottom) indicates this trend holds for thiophenol and 4-nitrophenol esters 
as well. Enzymatic reaction conditions: 1 mM Pik hexaketide, 8 mM 2-vinylpyridine, 1 mol% Pik 
TES148C (10 μM), 4 hours, RT. Conversion to 9 was monitored (HPLC) with data represented as the 
mean ± standard deviation where n = 3.  
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similar procedure used previously.27 Kinetic analysis revealed that the serine to cysteine 
substitution afforded a superior cyclization catalyst for each substrate tested. Pik 
Scheme 3.3 Pik TES148C displays increased substrate flexibility. Evaluation of methyl protected 
epimerized Pik Hexaketide with Pik TES148C. Enzymatic reaction conditions: 1 mM Pik hexaketide, 8 
mM 2-vinylpyridine, 1 mol% Pik TES148C (10 μM), 4 hours, RT. Conversion to 16 was monitored 
(HPLC) with data represented as the mean ± standard deviation where n = 3.  
Table 3.4 Steady state kinetic values for Pik TEWT and TES148C. 
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TES148C displayed a 4.3 and 12-fold increase in the kcat/Km for macrolactonization of both 
the native (1) and C-3 methoxy hexaketide 13 compared to Pik TEWT, respectively. In 
reactions containing methyl protected epimerized 14, not only did Pik TES148C retain the 
ability to catalyze macrolactonization of the linear substrate, but notably the kcat/Km was 
5.5-fold higher than Pik TEWT catalyzed hydrolysis. In addition to increased substrate 
flexibility of Pik TES148C, the gain-of-function mutation provided a 2.6-fold rate 
enhancement with the native hexaketide 4 over wild type. These kinetic parameters 
demonstrate that the S148C mutation of Pik TE produces a catalyst with both expanded 
substrate scope and increased catalytic efficiency 
 
PikAIII-TES148C with diastereomeric pentaketides 
We next investigated whether the engineered Pik TES148C was able to improve 
substrate flexibility in the context of full-module catalysis. To accomplish this, we 
generated PikAIII-TES148C and incubated it with the diastereomeric series of Pik 
pentaketides reported in Chapter II.  LC-HRMS analysis of reaction products revealed 
two new peaks in the chromatograms not observed in PikAIII-TEWT reactions (Figure 
3.5), with masses and retention time corresponding to 12-membered ring 
macrolactones.  As no authentic standards for the putative novel products were 
available, a 0.2 millimole scale reaction of 17 with PikAIII-TES148C was performed and 
the reaction products were purified and characterized via MS and NMR. Structural 
determination of the reaction products confirmed that PikAIII-TES148C was indeed able to 
generate 11-epi-10-dml 20 from 17, as well as 3-keto-11-epi-10-dml 23, due to failed 
reduction of the β-keto intermediate by the PikAIII KR domain prior to transfer to the 
terminal TE domain (Scheme 3.4).   
Diminished relative KR activity has been previously observed in vitro by the 
production of both the predicted reduced and 3-keto macrolactones from reactions 
containing Ery5-TE with DEBS pentaketide.56 Additionally, PikAIII-PikAIV chimeras57 
lacking a KR domain yielded exclusively 3-keto-10-dml when incubated with Pik 
pentaketide in vivo, indicating that the WT Pik TE domain is capable of cyclizing the C-3 




Figure 3.5 Incubation of diasteromeric pentaketides with PikAIII-TES148C. LC-HRMS analysis of 
reactions containing the stereoisomeric substrate panel. (a) Reaction scheme of stereoisomer 
pentaketides with predicted macrolactone products. The * indicates a species detected by LC-HRMS. 
(b) LC-HRMS chromatogram of reactions with PikAIII-TEWT (black traces) or PikAIII-TES148C (red 
traces). Blue trace is authentic 10-dml (5) standard. Traces were generated by monitoring the 
extracted ion chromatogram of each reaction for the 12-membered macrolactone [M+H]
+
 ion at 297.20 




PikAIII-TES148C reactions with 17 also occurred with the native Pik pentaketide (1). 
Accordingly, we performed analytical scale reactions containing PikAIII-TES148C with its 
native substrate and analyzed the product distribution using synthetic standards for 
each product. HPLC quantification of the reaction products revealed the conversion of 
native pentaketide to 3-keto-10-dml 24 and 10-dml (5) to be 5.5% and 12.5%, 
respectively (Scheme 3.5). Generation of both the reduced and unreduced 
macrolactone products indicates competition for the linear hexaketide intermediate 
between the KR and TE domains even in the context of the native substrate. Isolation of 
20 and 23 at 12% yields indicates that the identified thioesterase bottleneck had been 
alleviated by a single amino acid change (S148C) enabling substrate flux to generate 
novel epimerized macrolactones. The product distribution indicates competition 
between the KR mediated β-keto reduction and TE cyclization of the linear hexaketide 
Scheme 3.4 Reaction of PikAIII-TES148C with C-9-epimerized pentaketide 17. Enzymatic reaction 
conditions: 1 mM Pik pentaketide, 20 mM (20 equiv) MM-NAC, 8 mM (8 equiv) 2-vinylpyridine, 0.5 
mM (50 mol%) NADP+, 2.5 mM (2.5 equiv) glucose-6-phosphate, glucose-6-phosphate 
dehydrogenase (2 units/mL), 3 μM (0.3 mol%) PikAIII-TE, 8 hours, stationary, RT. 
 
Scheme 3.5 Reaction of PikAIII-TES148C with native pentaketide 1. Enzymatic reaction conditions: 1 
mM Pik pentaketide, 20 mM (20 equiv) MM-NAC, 8 mM (8 equiv) 2-vinylpyridine, 0.5 mM (50 mol%) 
NADP+, 2.5 mM (2.5 equiv) glucose-6-phosphate, glucose-6-phosphate dehydrogenase (2 




intermediate. This competition is remarkable since the KR domain is fully competent 
toward processing the native substrate and no unreduced products are observed in 
reactions containing PikAIII-TEWT, suggesting that the engineered TE domain is able to 
outcompete the native catalytic sequence.58,59 While this domain competition for the 
hexaketide intermediate diminished the product yields for 11-epi-10-dml 20, it provides 
insight into the effects of engineered domains on the sequence of catalytic events in 






PKS and TE Biochemistry  
Purified H2O from a Millipore Milli-Q system with Millipore Q-Gard 2/Quantum Ex 
Ultrapure organex cartridges was used for all cell culture, protein purification, and 
enzymatic reactions. E. coli seed culture was grown in 15 mL sterile tubes, and 
subsequently grown in Corning Fernbach flasks (2.8 L) with 3x deep baffles.  LB broth 
(Miller) and glycerol were obtained from EMD.  Isopropyl-β-D-thiogalactopyranoside 
(IPTG) and Kanamycin (Kan) sulfate were obtained from Gold Biotechnology.  
Streptomycin sulfate (Strep) was obtained from AK scientific.  NaCl, CaCl2 and 
imidazole were obtained from Fisher Scientific. Lysozyme was purchased from RPI.  
Benzonase was purchased from Sigma Aldrich.  PD-10 columns were purchased from 
GE scientific and equilibrated with 5 column volumes of storage buffer before use.  Ni-
NTA agarose resin was purchased from Qiagen and pre-equilibrated with five column 
volumes of lysis buffer before use.  
A Symphony SB70P pH meter was calibrated according to the manufacturer’s 
specifications and used to monitor the pH of all solutions during adjustment. Cells were 
lysed using a 550 Sonic Dismembrator purchased from Fisher Scientific.  Optical 
density (OD600) was determined using an Eppendorf Biophotometer.  All solutions were 
autoclaved or sterile filtered through a 0.2 μm filter.   
 
Buffers:  
lysis: HEPES (50 mM), NaCl (300 mM), imidazole (10 mM), glycerol (10% v/v), pH 8.0. 
wash: HEPES (50 mM), NaCl (300 mM), imidazole (30 mM), glycerol (10% v/v), pH 8.0. 
elution HEPES (50 mM), NaCl (300 mM), imidazole (300 mM), glycerol (10% v/v), pH 
8.0. 
storage: HEPES (50 mM), NaCl (150 mM), EDTA (1 mM), glycerol (20% v/v), pH 7.2. 
PikAIV reactions:  sodium phosphate (400 mM), glycerol (20% v/v), 2-vinylpyridine (8 
mM), pH 7.2. 




Stock solutions: hexaketide substrates (50 mM in DMSO), 2-vinylpyridine (500 mM in 
DMSO), ascorbic acid (500 mM in H2O), sodium metabisulfite (100 mM in H2O), PikAIV 
reaction buffer [2x, sodium phosphate (800 mM), glycerol (40% v/v), pH 7.2], Pik TE 
reaction buffer [2x, sodium phosphate (800 mM), pH 7.2], MM-SNAC (500 mM in H2O, 
neutralized to pH 7.2 with NaHCO3). 
 
Protein Expression 
The cloning, expression and purification of PikAIV60 and the Pik TE61 has been reported 
previously. The cysteine mutant of Pik TE was generated from a pET28 plasmid 
encoding wild type Pik TE34 by substitution of the native codon 148 TCC to TGT using 
the QuikChange site-directed mutagenesis (Stratagene) protocol. Identical protocols 
were used for the expression and purification of Pik TES148C. 
A starter culture was generated by inoculating 5 mL of LB broth containing Kan (50 
mg/L) with fresh transformants of E. coli (BAP1)62 cells containing the corresponding 
plasmids for expression of the respective PKS proteins and grown overnight at 37 ˚C. 
Following the overnight growth, the entire starter culture was subsequently used to 
inoculate an expression culture of 1 L of TB containing Kan (50 mg/L) and grown at 37 
˚C to an OD600 of 0.3-0.4. The expression cultures were then cooled to 18 ˚C and 
growth was maintained until an OD600 of 0.7-0.8 was reached, at which point protein 
expression was induced via addition of IPTG (350 µM) and the cultures were incubated 
at 200 RPM at 18 ˚C for 20 hours.  
 
Protein Purification   
To retain maximum enzymatic activity, the following purification procedure was 
performed at 4 ˚C in less than 2 hours. Overexpression cultures were harvested by 
centrifugation (5,500 x g, 10 min, 4 ˚C) and cell pellets were suspended in 5 mL of lysis 
buffer per gram of cells via vortex. Cell lysis was accomplished by gentle agitation at 4 
˚C with 0.4 mg/ml lysozyme and 8 units/ml benzonase for 30 min followed by sonication 
on ice (6 x 10s with 50s rest periods). Cellular debris was pelleted by centrifugation 
(40,000 x g, 15 min, 4 ˚C), and the supernatant applied to 3 mL of Ni-NTA resin. After 
binding, the column was washed with 25 mL of wash buffer under gentle syringe 
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pressure and the target protein was eluted with 15 mL of elution buffer. Protein 
containing fractions were assessed via their absorption at 280 nm, pooled, and buffer 
exchanged into storage buffer using a PD-10 column. Finally, protein containing 
fractions were determined via their absorption at 280 nm, pooled, flash frozen in liquid 
N2, and stored at -80 ˚C.  
 
Enzymatic reactions 
Analytical Enzymatic Reactions 
All enzymatic reactions were performed in triplicate at a volume of 50 μL and were 
initiated via the addition of enzyme. 2-vinylpyridine (Sigma) was employed as a thiol 
scavenger (8 mM final concentration) in all reactions. After 4 hour stationary incubation 
at RT, the reactions were quenched with 3 volumes of MeOH (150 μL), clarified by 
centrifugation (17,000 x g, 15 min, 4 ˚C) and analyzed for macrolactone production. In 
all cases, the reactions were carried out in PikAIV or Pik TE reaction buffers.  
 
Methyl Protected Substrates: 
Reactions employing methylated substrates were performed as one-pot reactions 
containing phosphate buffer, methylated hexaketide (1 mM), with or without MM-SNAC 
(20 mM). Catalysis was initiated via the addition of enzyme, and incubated for 4 hours. 
Conversion to macrolactones was monitored by Method A (HPLC analysis section). 
 
NBOM Protected Substrates: 
Enzymatic reactions utilizing NBOM protected substrates were performed over two 
steps. First, a solution of ascorbic acid (25 mM final concentration), sodium 
metabisulfite (1 mM final concentration), NBOM protected substrate (1 mM final 
concentration), and H2O (requisite dead volume) was irradiated under a consumer facial 
tanning lamp at a height of 14 cm (Verseo #AH129c) for 20 min to furnish the 
deprotected Pik hexaketide. NOTE: Irradiation through the side of the microtubes 
employed (Axygen #MCT-175-C) did not interfere with photolysis, and this process was 
reproducible over the course of this study. After photolysis, the solution was diluted with 
either PikAIV of Pik TE reaction buffer, MM-NAC (20 mM final concentration when 
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included). Catalysis was initiated via the addition of enzyme, and incubated for 4 hours. 
Conversion to macrolactones was monitored by Method B (HPLC analysis section). 
 
HPLC analysis 
Macrolactone production was monitored via analytical high performance liquid 
chromatography (HPLC) using a Beckman Coulter instrument (model 366 serial 385-
1160) and a Zorbax SB-Phenyl 3.5 μM 4.6 x 150 mm column (part number 863953-912) 
at a wavelength of 250 nm. 
Method A: For reactions employing methylated substrates, separation was 
accomplished by the following method: 3.0 mL/min, solvent A: H2O, solvent B: MeCN, 
20% B 0-1 min, 20-60% B linear gradient 1-10 min, 100% B 10-11 min, 20% B 11-12 
min. 
Method B: For reactions employing NBOM protected substrates, separation was 
accomplished by the following method: 3.0 mL/min, solvent A: H2O, solvent B: MeCN, 
10% B 0-1 min, 10-40% B linear gradient 1-10 min, 100% B 10-11 min, 10% B 11-12 
min. 
Samples were quantified by linear regression using equations derived from fitting the 
peak areas of the corresponding standard curves. Standard curves were generated by 
analyzing macrolactone standards in triplicate at a range of concentrations from 1.0-
0.0156 mM, representing a range in percent conversions from 400-6.5%, and were 
linear in all cases.  Conversions below 6.5% were quantified via extrapolation of the 
standard curve. 
 
LC-HRMS analysis  
Analytical liquid chromatography-mass spectrometry (LC-MS) was performed on an 
Agilent LC system (1290 series) coupled to an Agilent QTOF mass spectrometer (6500 
series) using a Phenomenex Synergi 4μ Hydro RP 100 x 2 mm column (serial 48836-5) 
heated to 50 °C. Method: 0.4 mL/min, A: H2O 0.1% formic acid, B: MeCN 0.1% formic 
acid, 0% B 0-2 min,0-100% B linear gradient 1-9 min, 100% 9-10 min, 100- 0% B 10-




Large scale reactions for product characterization 
Incubation of 14 with Pik TES148C: 
Reaction conditions: sodium phosphate buffer (400 mM, pH = 7.2), hexaketide 14 
(1mM), 2-vinylpyridine (8 mM), purified Pik TE (10 μM in reaction, 1 mol %), 18 hours, 
stationary, RT.  
Workup and purification:  The reaction was quenched with acetone (300 mL), filtered 
through a celite plug, concentrated by rotary evaporation, and extracted with EtOAc 
(3x). Flash chromatography employing EtOAc/hexanes (10:90) afforded compound 9 
(0.03 g, 0.09 mmol, 90%).  
1H-NMR (599 MHz; CDCl3): δ 6.59 (dd, J = 16.3, 8.0 Hz, 1H), 6.06 (d, J = 16.3 Hz, 1H), 
4.48 (ddd, J = 9.6, 7.1, 5.0 Hz, 1H), 3.45 (s, 3H), 3.18 (dd, J = 8.9, 1.8 Hz, 1H), 2.77-
2.65 (m, 3H), 2.08-2.02 (m, 1H), 1.80-1.75 (m, 2H), 1.62 (ddd, J = 14.3, 8.1, 5.9 Hz, 
1H), 1.26 (d, J = 7.0 Hz, 3H), 1.16-1.12 (ovlp m, 1H), 1.13 (d, J = 6.7 Hz, 3H), 1.09 (d, J 
= 6.7 Hz, 3H), 1.07 (d, J = 6.9 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). 
13C-NMR (151 MHz; CDCl3): δ 204.6, 173.5, 146.8, 128.8, 86.2, 80.8, 60.2, 42.8, 42.4, 
39.7, 36.6, 34.1, 25.0, 17.4, 16.2, 15.60, 15.45, 9.5 
HRMS: Calculated [M+H]+ 311.2217, found 311.2216. 
 
Incubation of 17 with PikAIII-TES148C: 
Reaction conditions: sodium phosphate buffer (300 mM, 15% v/v glycerol, 133 mL total, 
pH = 7.2), pentaketide 17 (48 mg, 0.13 mmol, 1 mM) MM-SNAC (20 equiv, 20 mM), 
NADP+ (0.5 equiv, 0.5 mM), glucose-6-phosphate (2.5 equiv, 2.5 mM), glucose-6-
phosphate dehydrogenase (2 units/mL), 2-vinylpyridine (8 mM), PikAIII-TES148C (3 μM, 
0.3 mol %), 12 hours, stationary, RT.  
 
Workup and purification:  Quenched with acetone (2x volume, 260mL), placed in a -20 
°C freezer for 1 hour and filtered through a celite plug.  Remaining insoluble material 
was suspended in acetone and this solution was used to rinse the celite plug.  Acetone 
was removed through rotary evaporation and the aqueous layer was saturated with 
NaCl and extracted 3x EtOAc. Combined organic layers were washed with brine and 
filtered through a sodium sulfate plug then rinsed 2x with EtOAc and concentrated. 11 
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and 12 were purified directly by preparatory HPLC using a Phenomenex Luna C18, 5 
um, 250 x 21.2 mm column (serial 444304-4) monitoring at 250 nM. Method 9 mL/min, 
A: H2O 0.1% formic acid, B: MeCN 0.1% formic acid, 25% B 0-5 min, 25-40% B linear 
gradient 5-25 min, 60% B 25-30 min, 60-90% B linear gradient 30-50 min,100% B 50-65 
min, 25% B 65-75 min. 
 
20 from pentaketide 17 (4.8 mg, 0.016 mmol, 12% yield). 
1H NMR (700 MHz; CD3OD): δ 6.39 (dd, J = 15.9, 9.2 Hz, 1H), 6.19 (d, J = 15.9 Hz, 
1H), 4.44 -4.38 (m, 1H), 3.51 (dd, J = 9.5, 2.0 Hz, 1H), 2.73-2.64 (m, 2H), 2.53-2.47 (m, 
1H), 2.19-2.14 (m, 1H), 1.93-1.91 (m, 2H), 1.83-1.75 (m, 2H), 1.49-1.43 (m, 1H), 1.27 
(d, J = 7.0 Hz, 3H), 1.08 (d, J = 6.7 Hz, 3H), 1.06 – 1.03 (m, 6H), 0.93 (t, J = 7.4 Hz, 
3H). 
13C NMR (700 MHz; CD3OD): δ 207.3, 176.2, 147.9, 131.5, 83.2, 77.5, 46.4, 43.6, 42.7, 
37.2, 36.3, 25.9, 17.4, 17.3, 17.0, 16.3, 10.4. 
HRMS: Calculated [M+H]+ 297.2060, found 297.2046 
 
23 from pentaketide 17 (4.8 mg, 0.016 mmol, 12% yield). 
1H NMR (700 MHz; CD3OD): δ 6.43 (dd, J = 15.6, 9.1 Hz, 1H), 6.28 (d, J = 15.6 Hz, 
1H), 4.74 (td, J = 8.9, 3.2 Hz, 1H), 3.87 (q, J = 6.8 Hz, 1H),  3.07-3.02 (m, 1H), 2.77-
2.71 (m, 1H), 2.59-2.53 (m, 1H), 1.97–1.84 (m, 3H), 1.66-1.58 (m, 1H), 1.20 (d, J=6.8 
Hz, 3H), 1.17 (d, J = 7.2 Hz, 3H), 1.08 (d, J = 6.8 Hz, 3H), 1.06 (d, J = 6.7 Hz, 3H), 0.94 
(t, J = 7.4 Hz, 3H). 
13C NMR (700 MHz; CD3OD): δ 209.1, 206.1, 171.3, 148.8, 132.1, 80.1, 52.6, 47.2, 
45.1, 42.6, 38.7, 26.2, 18.1, 17.8, 16.1, 14.3, 9.6.  
HRMS: Calculated [M+H]+ 295.1904, found 295.1902 
 
Kinetic analysis of thioesterase catalysis 
Product formation for all kinetic experiments was quantified by linear regression using 
equations derived from fitting the peak areas of the corresponding standard curves. 
Standard curves were generated by analyzing product standards in triplicate at a range 
of concentrations and were linear in all cases. Prior to performing kinetic analysis, the 
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pH dependence for TE macrolactonization was established by running a series of 
assays at pH 6, 6.5, 7, 7.2, 7.5, 7.8, 8. The reactions consisted of sodium phosphate 
buffer (50 mM), 1 μM Pik TE (WT or S148C), 1 mM 4 and 10% (v/v) DMSO in a total 
volume of 50 μL. The reactions were incubated at RT for 1 h and quenched by addition 
of MeOH (150 μL). All reactions were run in duplicate and following centrifugal 
clarification (17,000 x g, 15 min, 4˚C) the samples were directly analyzed for product 
formation, pH 7.2 was found to be optimum. 
 
Macrolactonization of 4: 
Macrolactonization of the native hexaketide 4 was monitored via analytical high 
performance liquid chromatography (HPLC) using an Agilent 1100 Series HPLC and a 
Zorbax SB-Phenyl 3.5 µm, 4.6 x 150 mm (part number 863953-912) column at a 
wavelength of 250 nm. Products were separated using a linear gradient via the following 
method: 3.0 mL/min, solvent A: H2O, solvent B: MeCN, 10% B 0-1 min, 10-40% B linear 
gradient 1-10 min, 100% B 10-11 min, 10% B 11-12 min. 
A time course for the cyclization reaction with each TE was accomplished by incubating 
assay mixtures containing 400 mM phosphate buffer (pH 7.2), 10% (v/v) DMSO, 0.125 
mM 4, and 0.3 μM TES148C or 1.0 μM TEWT in a total reaction volume of 350 μL at room 
temperature for intervals of 5, 10, 20, and 30 min, at which point they were quenched 
and analyzed via HPLC. The NBOM protected substrate was deprotected and utilized in 
enzymatic reactions as previously reported34, briefly: a solution of ascorbic acid (25 mM 
final concentration), sodium metabisulfite (1 mM final concentration), NBOM protected 
hexaketide (1 mM final concentration), and H2O (requisite dead volume) was irradiated 
under a consumer facial tanning lamp at a height of 14 cm (Verseo #AH129c) for 20 min 
to furnish the deprotected Pik hexaketide 4. After photolysis, the solution was diluted 
with enzymatic reaction buffer, and catalysis was initiated via the addition of enzyme. 
Reactions were run in duplicate and the velocities were determined to be linear by linear 
regression analysis of the data over a period of 20 min. 
Steady-state kinetic analysis was performed by determining the initial velocities for the 
macrolactonization of 4 at concentrations of 0.125 mM, 0.25 mM, 0.5 mM, 1 mM, 2 mM, 
3 mM, 4 mM, 6 mM, and 8 mM. The reactions consisted of 400 mM phosphate buffer 
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(pH 7.2), 10% (v/v) DMSO, variable concentrations of 4, and 0.3 μM TES148C or 1.0 μM 
TEWT. The reactions were incubated at room temperature for 10 min at which point they 
were quenched and analyzed via HPLC for macrolactone production. All reactions were 
run in triplicate and the Initial velocities at different substrate concentrations were fit to 
the Michaelis-Menten equation by nonlinear least-squares regression to calculate kcat 
and KM. 
 
Macrolactonization of 13: 
Macrolactonization of SNAC-MeHK 13 to 9 was monitored via analytical high 
performance liquid chromatography (HPLC) using an Agilent 1100 Series HPLC and a 
Zorbax SB-Phenyl 3.5 µm, 4.6 x 150 mm (part number 863953-912) column at a 
wavelength of 250 nm. Products were separated using a linear gradient via the following 
method: 3.0 mL/min, solvent A: H2O, solvent B: MeCN, 20% B 0-1 min, 20-60% B linear 
gradient 1-10 min, 100% B 10-11 min, 20% B 11-12 min. 
A time course for the macrolactonization reaction of each TE at pH 7.2 was obtained by 
analyzing reaction mixtures containing 400 mM phosphate buffer (pH 7.2), 10% (v/v) 
DMSO, 0.2 mM 13, and 0.3 μM TES148C or 1.0 μM TEWT in a total reaction volume of 
1500 μL incubated at room temperature for intervals of 5, 10, 20, and 30 min at which 
point they were quenched and analyzed via HPLC for macrolactone production. 
Reactions were run in duplicate and the velocities were determined to be linear by linear 
regression analysis of the data over a period of 20 min. 
 
Steady-state kinetic analysis was performed by determining the initial velocities for the 
macrolactonization of 13 at concentrations of 0.25 mM, 0.5 mM, 1 mM, 2 mM, 3 mM, 4 
mM, 6 mM, and 8 mM. The reactions consisted of 400 mM phosphate buffer (pH 7.2), 
10% (v/v) DMSO, variable concentrations of 13, and 0.3 μM TES148C or 1.0 μM TEWT. 
The reactions were incubated at room temperature for 10 min at which point they were 
quenched with MeOH (150 μL) and analyzed via HPLC for macrolactone production. All 
reactions were run in triplicate and the initial velocities at different substrate 
concentrations were fit to the Michaelis-Menten equation by nonlinear least-squares 
regression to calculate kcat and KM. The 6 mM and 8 mM concentration points were 
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omitted from the plots with TES148C as these concentrations resulted in significant 
substrate inhibition.  
 
Hydrolysis and macrolactonization of 14:  
The hydrolysis (TEWT) and macrolactonization (TES148C) of 14 to either 9 or 15, 
respectively, was monitored via HPLC using the same method as above for 13. A time 
course for the hydrolysis and cyclization reaction for each TE was accomplished by 
incubating assay mixtures containing 400 mM phosphate buffer (pH 7.2), 10% (v/v) 
DMSO, 0.03 mM (TES148C) or 0.125 mM (TEWT) 14, and 0.3 μM TES148C or 1.0 μM TEWT 
in a total reaction volume of 1500 μL at room temperature for intervals of 5, 10, 20, and 
30 min, at which point they were quenched and analyzed via HPLC. Reactions were run 
in duplicate and the velocities were determined to be linear by linear regression analysis 
of the data over a period of 30 min.  
 
Steady-state kinetic analysis was performed by determining the initial velocities for the 
macrolactonization and hydrolysis of 14 at concentrations of 0.25 mM, 0.5 mM, 1 mM, 2 
mM, 3 mM, 4 mM, 6 mM, and 8 mM for TEWT and 0.03 mM, 0.06 mM, 0.125 mM, 0.25 
mM, 0.5 mM, 1 mM, 2 mM, 3 mM, 4 mM, 6 mM, and 8 mM for TES148C. The reactions 
consisted of 400 mM phosphate buffer (pH 7.2), 10% (v/v) DMSO, variable 
concentrations of 5, and 0.5 μM TES148C or 1.0 μM TEWT. The reactions were incubated 
at room temperature for 10 min at which point they were quenched and analyzed via 
HPLC for product formation. All reactions were run in triplicate and the Initial velocities 
at different substrate concentrations were fit to the Michaelis-Menten equation by 
nonlinear least-squares regression to calculate kcat and KM. The concentration points not 
represented were removed from the plot as they resulted in significant substrate 
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Introduction     
Pik TE belongs to the α,β-hydrolase class of serine hydrolases and contains the 
characteristic Ser-His-Asp catalytic triad.1 X-ray crystallographic studies have shown Pik 
TE functions as a dimer and the catalytic triad (Ser148, His268, Asp176) lies at the 
center of a long open substrate channel that spans the entire width of the enzyme2 
(Figure 4.1). In vivo, Pik TE receives its substrate as a thioester tethered to the 
phosphopantetheinyl arm of the ACP domain from the upstream module. It is believed 
that the substrate entrance site is located at the N-terminal portion of the protein, while 
the product exits the C-terminal side. Structural studies of Pik TE trapped as an acyl-
enzyme with covalent phosphonate affinity labels have provided further insights into the 
Pik TE catalytic mechanism.3,4 By solving the 1.8-Å crystal structure of Pik TE in 
complex with the substrate mimic, Akey et al. report the existence of a “hydrophilic 
barrier” of water molecules that form at the protein exit site and serve to direct the 
hydrophobic acyl chain back into the substrate channel toward the location of 
nucleophilic attack. 4 Of note, there were remarkably few direct enzyme-substrate polar 
contacts and since the apo- and affinity label bound structures were essentially 
unchanged, it is unlikely that the protein utilizes an induced-fit mechanism for substrate 
recognition. Thus while these studies provided significant insight into the Pik TE 
catalytic mechanism, many questions remain as to how Pik TE discriminates among 
candidate substrates and what are the structural parameters that govern 
macrolactonization over hydrolysis after formation of the acyl-enzyme intermediate.  
 
Trapping the TE acyl-enzyme intermediate 
Following the remarkable results with Pik TES148C from Chapter III, we were 
motivated to explore the structural and mechanistic parameters that govern 
macrolactonization in Pik TE. Intrigued by the stark catalytic divergence from 
macrolactonization to hydrolysis in Pik TE reactions containing a hexaketide bearing the 
epimerized C-11 hydroxyl group (Scheme 3.2), we pursued x-ray crystallographic 




Figure 4.1 Overall structure of the Pik TE dimer. (a) Surface (blue) and cartoon (yellow) 
representation of the global Pik TE crystal structure. (b) Magnified view of the Pik TE substrate 
channel traversing the entirety of the protein, with the residues comprising the catalytic triad colored 






divergent catalysis. At the initiation of this project, we reasoned that trapping Pik TE as 
an acyl-enzyme intermediate with its full length native substrate as opposed to affinity 
label mimics would provide the best insight into the mechanisms that govern productive 
catalysis.  
A literature search of related protein co-crystal structures revealed a promising 
strategy for trapping substrates previously  employed in fatty acyl-CoA thioesterase II.5 
In this scheme, Witkowski et al. successfully converted a hydrolase to an acyl-
transferase through the mutation of two active site residues. The mutations performed 
included a Ser to Cys and a His to Arg substitution of the native residues within the 
catalytic triad. We speculated these mutations were able to stabilize the acyl-enzyme 
intermediate through the following general mechanism: Substitution of the native serine 
to a cysteine generates an active site residue with increased nucleophilicity and 
decreased pKa, resulting in a faster rate of acylation. Mutation of the His residue 
responsible for the activation of water during substrate hydrolysis is critical for stabilizing 
the thioester intermediate after formation of the acyl-enzyme intermediate (Figure 4.2). 
Since PKS TE domains share an analogous catalytic triad, we expected that this 
strategy could be successfully applied to Pik TE.  
To pursue this strategy, we performed the analogous mutations in Pik TE (S148C 
and H268R) and expressed this mutant for in vitro analysis. Unfortunately, we found 
that Pik TES148CH268R expressed predominantly in the insoluble protein fraction and was 
recalcitrant to purification. In order to facilitate in vitro analysis, we fused Pik 
TES148CH268R with a solubilizing maltose binding protein (MBP) tag at the N-terminus. 
The MBP-tagged protein expressed strongly in the soluble cell lysate fraction and 
following purification with TEV mediated removal of the MBP tag, we obtained soluble 
Pik TES148CH268R in quantities suitable for initial testing (Figure 4.3). Purified Pik 
TES148CH268R was tested for enzymatic activity using conditions previously employed with 
Pik TEWT (Chapter III) and found to be inactive (Figure 4.4), indicating that the mutation 
strategy successfully eliminated catalytic turnover of the enzyme.   
Since the single mutant Pik TES148C behaved comparably to the wildtype protein, 
we reasoned that the cause for the Pik TES148CH268R insoluble expression was due to the 
H268R substitution and thus generated a series of mutants at this position to test for 
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increased solubility. We performed mutations at position 268 to include Gly, Ala, Asn, 
and Gln and ultimately Pik TES148CH268Q provided the highest soluble expression and 
was purified readily as a standalone protein (Figure 4.5). We next screened conditions 
suitable for performing the substrate labelling reactions with Pik TES148CH268Q. We 
anticipated a high pH buffer would increase the efficiency of the acylation reaction as 
the cysteine nucleophile would be in its more nucleophilic thiolate form. An extensive 
survey of buffers, additives, temperature, and time of incubation yielded optimized 
conditions suitable for achieving approximately 80% labelling after overnight incubation 
(Figure 4.6). The stable formation of Pik TE in complex with its native substrate 
demonstrates the success of this mutation strategy for trapping type I PKS TE domains 
as acyl-enzyme intermediates for downstream structural and functional studies. After 
optimizing reaction conditions, we performed large scale labeling experiments followed 
by gel filtration chromatography in efforts to provide material suitable for X-ray 
crystallography. Unfortunately, we have been unable to form crystals from the acyl- 
Figure 4.2 General mechanism for trapping the TE acyl-enzyme intermediate through mutation of the 




enzyme intermediate to date and are actively pursuing broad screening conditions for 
crystallization. Current studies are also focused on applying these techniques to 
homologous TE domains with native and non-native substrates to generate material 
suitable for X-ray crystallography. If successful, these X-ray crystallography studies 
should provide significant insight into the structural and mechanistic parameters that 
govern macrolactonization in PKS TE domains. 
Figure 4.3 Expression and purification of MBP-Pik TES148CH268R for substrate trapping studies. (a) 
Analysis of BL21 (DE3) E. coli expression cultures showing the soluble production of MBP-Pik 
TES148CH268R (75 kDa). (b) TEV mediated MBP tag removal and subsequent isolation of untagged Pik 
TES148CH268R  (32 kDa). Lanes: 1. Insoluble cell lysate. 2. Soluble cell lysate. 3/4. Ni-NTA purification of 
the soluble cell lysate from Lane 2. 5. Purified protein after 8 hour TEV cleavage. 6. Removal of MBP 





Figure 4.4 In vitro analysis confirms that Pik TES148CH268R is catalytically inactive. Reactions containing 
1 with Pik TEWT (black trace) produce the cyclization and hydrolysis products 3 and 4, respectively. 
Incubation with Pik TES148CH268R (red trace) fails to produce either product, indicating the protein is 
unable to turn over the substrate. Enzymatic reaction conditions: 1 mM Pik hexaketide, 8 mM 2-






Figure 4.5 Pik TES148CH268Q is more amenable to in vitro analysis than TES148CH268R. (a) Gel filtration 
chromatogram from the purification of Pik TES148CH268Q showing a homogeneous, monodisperse 




Figure 4.6 LC-HRMS analysis of Pik TES148CH268Q substrate labelling reactions. The total ion 
chromatograms are displayed above and the deconvoluted mass below. (a) Overnight incubation with 
DMSO yields the apoprotein with calculated a mass of 33753 kDa observed with loss of the N-terminal 
methionine (33622 kDa) and phosphogluconylation
21
 (33800 kDa). (b) Addition of the C-3 methyl 
protected Pik hexaketide 1 yields the acyl-enzyme intermediate with a calculated mass increase of 
311 Da at approximately 80% incorporation. 
 
 




 In addition to pursuing X-ray crystallography, we envisioned that performing 
molecular dynamics (MD) simulations of Pik TE acylated with hexaketides 1 and 2 could 
provide structural insight into our experimentally observed catalytic divergence. 
Accordingly, we performed MD simulations of Pik TEWT modeled as acyl-enzyme 
intermediates bound to the C-3 methyl protected hexaketides (denoted Pik TE-1 and Pik 
TE-2, respectively, Figure 4.7), using the conformation of the derivatized products6 as 
the starting arrangement for the individual substrates. MD simulations were initiated with 
the hexaketide C-11 alcohol constrained in a reactive conformation by imposing a 
maximum distance restraint of 2.3 Å between the hexaketide nucleophilic hydroxyl 
hydrogen and the Nε nitrogen of His268. After 50 ns, the distance restraint was 
removed and the simulations were allowed to continue for 500 ns.  
 Clustering analysis of the resulting simulations based on the conformation of the 
acyl-enzyme intermediate was used to bin each frame into representative clusters of 
structures. The clusters were subsequently examined for hydrogen-bond and 
hydrophobic interactions involving the substrate and TE using LigPlot+.7 Examination of 
Figure 4.7 Acyl-enzyme starting structures for the MD simulations. Input structures for Pik TE 





the overall protein root-mean-square deviation (RMSD) and per-residue root-mean-
square fluctuation (RMSF) values for the trajectories of each TE complex demonstrated 
stable dynamic behavior throughout the course of the simulations, with Pik TE-2 
maintaining a slightly increased level of flexibility (Figure 4.8). Investigation of the Pik 
TE-2 residues that displayed higher RMSF values revealed these residues were located 
predominantly in loops and linker regions with higher intrinsic flexibility and had limited 
impact on the conformation of the hexaketide.  
Simulations of Pik TE-1 revealed that while the initial catalytic restraint was in 
place, the native hexaketide readily adopts two main conformations favorable towards 
macrolactonization (denoted as I and II, Figure 4.9a). At the initial stages of the 
simulation, conformation I predominates, accompanied with a high level of shape 
complementarity with the TE active site. The main interactions constituting conformation 
I are hydrophobic contacts between the hexaketide and the side chains of residues 
lining the active site. Additionally, a hydrogen bond between the hexaketide C-7  
Figure 4.8 Examination of the overall structural flexibility of the TE domain during the MD simulations. 
The RMSD (a) and RMSF (b) values for the 550 ns production MD simulations of Pik TE-1 (blue) and 







Figure 4.9 Comparison of the reactive conformations for each acyl-enzyme intermediate obtained 
from clustering analysis of MD simulations with Pik TEWT. (a) Pik TE-1 and (b) Pik TE-2. Pik TE-1 
conformations I and II contain a hexaketide orientation most conducive to macrolactonization with the 
C-11 OH in close proximity to both His268 and the C-1 carbonyl. The corresponding conformation 
(cluster I’) in the Pik TE-2 simulation likely represents a larger barrier to macrolactonization as the 
distance between the C-11 OH and His268 has increased and the resulting geometry hinders 
deprotonation. The Pik TE-2 hexaketide continues to evolve towards a linear conformation till the final 
cluster III’ is reached which places the C-11 OH distal to both His268 and the C-1 carbonyl and in an 
orientation susceptible to hydrolysis. The catalytic triad His268 and Asp176 residues are colored 
yellow. For each conformation the distance in angstroms from the nucleophilic hydroxyl oxygen to the 
Nε nitrogen of His268 and the ester C-1 carbonyl is displayed above the dashed lines. Clusters 
containing catalytically productive conformations contain red dashed lines. (c) The distance of the 
nucleophilic hydroxyl oxygen and the ester C-1 carbonyl plotted for each frame of the MD simulation 
with each data point colored according to the corresponding clustered conformation. The vertical 







carbonyl and the side chain of Thr77 facilitates stabilization of the cyclic, reactive 
conformation (Figure 4.10). After ~30 ns the hexaketide evolves to conformation II 
through a substrate tail rotation that places the C-11 alcohol 0.2 Å and 0.7 Å closer to 
His268 and the C-1 carbonyl, respectively. This orientation resembles the 
macrolactonization transition state (vide infra) even closer than conformation I and is 
likely catalytically productive. 
Following formation of conformation II, the hexaketide displays a large amount of 
conformational freedom within the TE active site. In the most prevalent conformation (III, 
Figure 4.9a) hydrophobic packing is largely reduced and non-productive hydrogen 
bonds between the C-11 alcohol and Tyr25/Leu193 are formed (Figure 4.10). Loss of 
the key hydrophobic interactions is detrimental to macrolactonization as it increases the 
conformational space accessible to the hexaketide, which adopts a more linear, 
unreactive conformation. Although conformation III accounts for the majority of the Pik 
TE-1 simulation, conformation II developed again later in the trajectory (406 to 443 ns, 
Figure 4.9c) suggesting that productive conformations for macrocyclization are 
frequently sampled despite the high substrate flexibility. 
The simulations of Pik TE-2 involving the C-11-epimerized hexaketide revealed a 
significantly different scenario. While the initial distance restraint was in place, the 
hexaketide adopted a cyclic conformation stabilized by hydrophobic packing with the TE 
active site (I’, Figure 4.9b). However, in contrast with the native hexaketide, the C-11 
alcohol of the epimerized hexaketide is prone to intramolecular hydrogen bonding with 
the C-1 carbonyl oxygen. Despite maintaining the substrate in a cyclic conformation with 
the nucleophilic hydroxyl in close proximity to the C-1 carbonyl, the resulting geometry 
impedes macrolactonization. Furthermore, His268 remains 4.0 Å away and positioned 
at an angle suboptimal for deprotonation, making this conformation catalytically 
unproductive. After ~80 ns, unrestricted Pik TE-2 transitions to the second most 
prevalent conformation that is primarily defined by interruption of the intramolecular 
hydrogen-bond and rotation of the hexaketide tail away from His268 resulting in poor 
shape complementarity with the TE active site and a more linear conformation of the 
hexaketide (II', Figure 4.9). These two unproductive conformations are alternately 
sampled for the majority of the simulation (~470 ns). Afterwards, the hexaketide chain 
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evolves towards even more extended conformations (III', Figure 4.9) characterized by a 
gradual loss of hydrophobic interactions with the protein, and formation of unproductive 
hydrogen bonds between the C-11 alcohol and Glu85 (Figure 4.10). This completely 
impedes macrolactonization and increases the likelihood competing hydrolysis of the 
acyl-enzyme intermediate will occur.  
Figure 4.10 The TE-hexaketide contacts identified from the clustering analysis of the Pik TEWT MD 
simulations. (a) Pik TE-1 and (b) Pik TE-2. Pik TE-1 clusters I and II stabilize the hexaketide in a 
catalytically productive conformation mainly by hydrophobic packing leading to a high level of shape-
complementarity and hydrogen bonding between the nucleophilic hydroxyl and the catalytic histidine.  
Conversely, cluster III shows decreased hydrophobic contacts and the hexaketide adopts a more 
linear conformation making it unreactive towards macrolactonization. Pik TE-5 Cluster I’ stabilizes the 
hexaketide in a cyclic conformation via hydrophobic packing; however the hexaketide adopts a 
conformation that impedes macrocyclization due to formation of an intramolecular hydrogen bond. 
Clusters II’ and III’ show a gradual loss of hydrophobic packing as the hexaketide adopts a linear 
conformation that makes it vulnerable to the experimentally observed hydrolysis. The catalytic triad 
His268 and Asp176 residues are colored yellow while the active site residues found to interact with the 
acyl-intermediate are colored green. Residues involved in hydrophobic interactions are displayed in 







We next compared the frequency of productive conformations sampled in the MD 
simulations by calculating quantum mechanically (QM) optimized macrolactonization 
transition structures (TS) for each hexaketide (vide infra). We used these models to 
describe the precise angle of nucleophilic attack (O11-C1-O1) and distance (O11-C1) 
for macrolactonization of each hexaketide. The resulting geometric values were then 
compared to those extracted from each frame of the corresponding MD simulations and 
the entire trajectories were plotted according to their deviation from the ideal TS values 
(Figure 4.11). Consistent with our clustering analysis of the hexaketide conformations, 
comparison of the geometric deviations from ideal within each simulation revealed that 
Figure 4.11 Procatalytic sampling of Pik TE during MD simulations. (a,b) Low energy QM optimized 
transition states for macrolactonization of Pik hexaketides (a) Pik TE-1 and (b) Pik TE-2. Non-polar 
hydrogens have been removed for clarity. (c,d) Deviations of the key catalytic distances (x axis) and 
angles (y axis) in the MD simulations of (c) Pik TE-1 and (d) Pik TE-2 from their respective optimized 
transition structure (green square at the origin of coordinates). Each point represents a single frame 
from the 550 ns simulation while the shaded rectangles represent frames from the MD that are likely in 







Pik TE-1 contained more frames with the hexaketide in a position favorable to 
macrolactonization (Figure 4.11c). In contrast, Pik TE-2 presented a larger distribution 
of geometries with very few catalytically productive structures (Figure 4.11d). Taken 
together, the MD results on the covalent acyl-enzyme intermediates indicate that 
hydrophobic interactions accompanying a high level of substrate-TE shape 
complementarity are critical for maintaining each hexaketide in a catalytically productive 
conformation. These contacts are, to a lesser extent, maintained in simulations 
containing the C-11-epimerized hexaketide 2, indicating that the Pik TE active site has 
sufficient flexibility to accommodate both epimers. The intrinsic conformational 
preferences of each hexaketide further influence catalysis. The acyl intermediates must 
reach conformations that are matched for deprotonation by His268 and subsequent 
nucleophilic attack in order to achieve macrolactonization. When these structural 
preferences are perturbed, as in the case with Pik TE-2, the energetic barrier to 
macrolactonization is increased above that of competing hydrolysis. 
 
Chemical lactonization 
As the MD simulations containing covalently bound hexaketides 1 and 2 revealed 
that both substrates are accommodated by the Pik TE active site, we next investigated if 
macrolactonization of the C-11-epimerized 2 suffered in bulk solution outside of 
enzymatic constraints. Starting with conditions employed for similar seco-acids8,9 we 
screened contemporary lactonization methodologies capable of cyclizing 4 to 3. 
Optimization of Yamaguchi conditions originally reported from the total synthesis of 
spinosyn analogs10, enabled direct comparison of lactonization efficiency of 4 and 5. 
Employing identical reaction conditions resulted in 73% and 6% conversions to 
generate 3 and 6, respectively (Scheme 4.1). This result confirmed the intrinsically poor 
reactivity of 5 toward macrocyclization compared to 4, corroborating the MD findings 
that the lack of macrolactone formation with the C-11-epimerized hexaketide is not due 
to steric clashes within the Pik TE active site. 
Synthetic, biomimetic macrolactonizations of macrolide cores predate 
biochemical studies of TE domains, with the total synthesis of erythronolide B first 
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reported in 1978.11 In the subsequent total synthesis of erythromycin A, Woodward and 
co-workers successfully generated the 9-dihydroerythronolide macrolactone only after 
screening 17 differentially protected seco-acids.12 The need for specific protecting group 
arrays to promote macrolactonization was rationalized through conformational biasing of 
the seco-acid.13 This conjecture was reevaluated using a C-9 reduced tetra-methylated 
seco-acid of 6-dEB lacking the extraneous hydroxyl groups at C-6 and C-12, and the 
authors found no biasing elements to be necessary.8 Of note, 9-dihydroerythronolide is 
a dihydroxylated analog of 6-dEB and not the native substrate for the DEBS TE. 
Difficulties associated with macrolactonization of 9-dihydroerythronolide are potentially 
due to unproductive conformations imparted by two additional hydroxyl groups at C-6 
and C-12, which, during biosynthesis, would be introduced after TE catalyzed 
macrolactonization by p450 hydroxylase tailoring enzymes. This discussion is meant to 
highlight the difficulties in biomimetic ring closure with analogs of polyketide natural 
products, where the conformation(s) necessary to enable macrolactonization may be 
perturbed from the natural, “competent conformation. ” The C-11-epimerized hexaketide 
5 represents one such analog where the stability of the cyclized product 6 is decreased.  
Unsurprisingly, chemical lactonization suffers relative to the methyl ether of native 
hexaketide 4 (6% and 73% conversion, respectively), though Pik TES148C is able to 
Scheme 4.1 Yamaguchi macrolactonization of methyl protected hexaketides. Conversion of 4 to 3 and 
5 to 6 was monitored by HPLC with data represented as the mean ± standard deviation where n = 3.  
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overcome the structural penalty imposed by C-11 epimerization thus improving 
conversion (94% and 83%, respectively). Of note, Pik TES148C catalysis operates using 1 
mol% enzyme in water at room temperature, avoiding large volumes of dry organic 
solvents, heating, and expensive Yamaguchi or Shiina reagents. 
 
QM calculations 
Since MD simulations revealed the Pik TEWT active site to be competent in 
binding the unnatural substrate 5, we hypothesized the catalytic advantages imparted 
by the S148C mutation were kinetic in nature as opposed to structural. To further our 
understanding of the energetics of these processes and how Pik TES148C is able to 
overcome the barrier to macrolactone formation with 5, we turned to QM modeling of 
the catalytic steps comprising macrolactonization after formation of the acyl-enzyme 
intermediate. To accomplish this, we generated abbreviated active site models 
(theozymes14) for Pik TEWT and Pik TES148C containing the native C-3-unprotected 
hexaketide (Pik TEWT-7 and Pik TES148C-7) and the C-11-epi hexaketide (Pik TEWT-8 
and Pik TES148C-8). Analysis of the resulting free energy landscapes revealed that 
macrolactonization of the linear hexaketide intermediates is an exergonic process in all 
four systems after product release (Figure 4.12). Cyclization of the native hexaketide 
was more thermodynamically favorable compared to C-11-epimerized hexaketide, 
particularly with the wild-type enzyme. Moreover, the macrolactonization mechanism 
with each TE was calculated to change from a stepwise addition-elimination with 
existence of a tetrahedral intermediate in Pik TEWT to a concerted acyl substitution
15 
upon the S148C mutation. This change in mechanism was evidenced by the flat 
potential energy surface which precludes the formation of a tetrahedral intermediate.  
Figure 4.13 shows the lowest energy transition structures and associated 
activation barriers (ΔG‡) for the macrolactonization of the acyl intermediates of both the 
natural 7 and C-11-epimerized 8 substrates with the Pik TEWT and TES148C protein 
models. The rate-limiting activation barriers for the TES148C catalyzed reactions are 
significantly lower than those for the TEWT reactions, which correspond to the final 
Ser148-acyl cleavage. Thus, Pik TES148C performs the macrolactonization of the native 
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and C-11-epimerized hexaketides with ΔG‡ values of 14.8 and 16.0 kcal mol-1, 
respectively, while Pik TEWT displays ΔG
‡ values of 18.2 and 22.4 kcal mol-1 for the 
same substrates (Figure 4.13). These values predict that the rate of reactions 
containing the native hexaketide after the formation of the acyl-enzyme intermediate is 
faster in Pik TES148C compared to TEWT.  
The calculated increase of 4.2 kcal mol-1 in the activation barrier of the 
macrolactonization of Pik TEWT-7 vs Pik TEWT-8, agrees well with the experimentally 
observed lack of epimerized-macrolactone formation. This higher macrolactonization 
energy barrier in the TEWT system increases the difficulty in proceeding from the acyl-
enzyme intermediate, which is vulnerable to water hydrolysis.16 While we did not 
observe significant water hydrolysis in reactions containing Pik TEWT and the native 
substrate, incubation with epimerized methyl protected 5 resulted exclusively in 
hydrolyzed product, the result of an inability to form the epimerized macrolactone 6. In 
Figure 4.12 Reaction coordinate diagram representing the relative free energies for Pik TE catalyzed 
macrolactonization of the native and C-11-epimerized hexaketides 7 and 8. Calculations were 
performed at the PCM/M06-2X/6-31+G(d,p) level using reduced models that define the enzymatic 
active site (theozymes
19
). Relative free energies are in kcal mol
-1
. Only the lowest energy conformers 
are represented. *This intermediate is higher in energy than its preceding TS due to conformational 







contrast, the 6.4 kcal mol-1 decrease in
 activation barrier for Pik TES148C-7 
macrolactonization is consistent with our experimentally observed product formation. 
 
Figure 4.13 Lowest energy rate-limiting transition structures calculated with PCM/M06-2X/6-31+G(d,p) 
for the abbreviated active site models (theozymes
14
) of the Pik TEWT (left) and Pik TES148C (right) 
catalyzed macrolactonization of native hexaketide 7 (top, in blue) and C-11-epi hexaketide 8 (bottom, 
in red). Activation free energies (ΔG
‡
) calculated form the corresponding Pik TE hexaketides are given 
in kcal mol
-1
 and distances in angstroms. Relevant breaking/forming C–O and C–S bonds are shown 
in boldface. Non-polar hydrogens have been removed for clarity.  
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Computational investigation of the Pik TE domain catalysis 
Our investigation revealed mutual recognition, TE-substrate shape 
complementarity, and intrinsic substrate structural preferences to be critical for the 
hexaketide to reach a conformation productive towards macrolactonization. MD 
simulations revealed hydrophobic interactions between the substrate and TE residues 
lining the active site as being vital for guiding the hexaketide to a catalytically competent 
pro-cyclic conformation. These findings are consistent with mutational analysis of DEBS 
TE where exchange of potential hydrogen-bonding residues did not substantively affect 
the specificity constant for hydrolysis of four unnatural thioester substrates. In this case, 
Wang and Boddy suggested that hydrophobic interactions between the active site and 
substrate are the main driving force of substrate specificity.17 Additionally, our results 
are in agreement with the available crystal structures of Pik TE bound with phosphonate 
substrate mimics, which displayed a lack of specific TE-substrate polar contacts.3,4  
Recently, Chen et al.18 reported theoretical investigations of the thioesterase 
domain from the erythromycin biosynthetic pathway (DEBS TE) to describe the 
mechanistic parameters that determine the catalytic partitioning of substrates to either 
macrocyclic or linear hydrolysis products. MD simulations coupled with QM calculations 
were performed on systems of DEBS TE modeled with the native DEBS heptaketide 
and Pik hexaketide, which both led to macrolactonization, as well as two diastereomers 
of a reduced C-7 hydroxyl analog of Pik hexaketide that result exclusively in substrate 
hydrolysis. Analysis of the resulting MD simulations provided findings consistent with 
those in this report, particularly highlighting the importance of the formation of a 
substrate pre-reaction state through induced-fit mutual recognition between the enzyme 
and the substrate for macrolactonization to occur. Consistent with the present study, the 
authors found a hydrogen bond between the lactonizing hydroxyl group of the substrate 
and the catalytic histidine as well as hydrophobic interactions to be critical for formation 
of a catalytically competent pre-reaction state.  
To understand the energetic consequences of the S148C mutation during the 
macrolactonization process, we performed DFT analysis of Pik TEWT and TES148C 
modeled as acyl-enzyme intermediates with the native and C-11-epimerized 
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hexaketides. The results of our QM calculations revealed a significant kinetic advantage 
in the reactions catalyzed by Pik TES148C. The S148C mutation provides a mechanistic 
change during the macrolactonization step from a two-step transesterification in the 
TEWT reaction (i.e. addition-elimination) to a lower energy single concerted step in the 
TES148C pathway.   
Overall, our combined computational method for investigating Pik TE catalysis 
using MD simulations in concert with QM calculations provides a plausible explanation 
for improved substrate flexibility and catalytic efficiency of Pik TES148C. According to the 
results from our MD simulations, epimerization of the hexaketide C-11 stereocenter 
generates a substrate with a reduced propensity for acquiring a catalytically competent 
conformation within the TE active site. However, the ability of the hexaketides to reach a 
conformation viable for catalysis is not the only factor affecting macrocylicization, 
especially if this step is not rate-limiting.18 Hence, even if a substrate has a poor 
propensity to arrange in a productive conformation and/or lactonization is structurally 
hindered (as with the C-11-epimerized hexaketide) a significant acceleration through a 
key single mutation can overcome these structural limitations, boosting reactivity even 
with unnatural substrates.  
Engineering TE domains  
Encouraged by the remarkable results achieved with the Pik TE S148C mutation, 
we next set out to investigate whether similar benefits could be obtained with additional 
PKS TE domains. For initial testing we chose the homologous DEBS and Juv TE 
domains (Figure 2.3 and 2.4) and introduced the analogous serine to cysteine 
substitution in each. The cysteine mutant of each TE was generated from a pET28 
plasmid encoding the corresponding wild type TE by substitution of the native serine 
codon using the QuikChange site-directed mutagenesis (Stratagene) protocol. 
Expression, purification, and analysis of DEBS TEWT and TES139C demonstrated that the 
Ser to Cys mutation imparted increased substrate flexibility consistent with the results 
from Pik TE. HPLC analysis of a single time point reaction containing the methyl 
protected N-acetylcysteamine Pik hexaketide 1 revealed that although DEBS TEWT was 
incompatible with the Pik substrate, DEBS TES139C was able to effectively generate 
97 
 
methyl protected 10-dml 3 (Figure 4.14). Analysis of Juv TEWT and TES142C is currently 
ongoing and future efforts will build upon our initial results with DEBS TES139C using an 
expanded the substrate scope to better understand the macrolactone analogs 




Figure 4.14 DEBS TES139C possesses increased substrate flexibility. Comparison of reactions 
containing DEBS TEWT (blue trace) and DEBS TES139C (red trace) confirms the gain-of-function 
processing of the methyl protected Pik hexaketide 1 to methyl 10-dml 3 (black trace) resulting from 
the Ser to Cys mutation. Enzymatic reaction conditions: 1 mM Pik hexaketide, 8 mM 2-vinylpyridine, 






Reactions were performed in dried glassware furnished through flame drying evacuated 
(<0.05 torr) flasks fitted with rubber septa containing PFTE coated magnetic stir bars 
backfilled with dry N2 and run under a positive pressure of dry N2 provided by mineral oil 
bubblers unless stated otherwise (open flask). Analytical thin-layer chromatography 
(TLC) was performed with EMD 60 F254 pre-coated glass plates (0.25 mm) and 
visualized using a combination of UV, p-anisaldehyde, KMnO4 stains. Room 
temperature (RT) reactions were conducted at ~23 °C, reactions run cooler than room 
temperature were performed in a cold room (4 °C), an ice bath (0 °C), or a dry 
ice/acetone bath (-78 °C). Commercial solvent purification system MBraun-MB-SPS # 
08-113 provided all dry solvents unless stated otherwise (technical grade). Flash 
column chromatography was performed using EMD 60 Gerduran® (particle size 0.04-
0.063) silica gel.  
  
TE Biochemistry 
Purified H2O from a Millipore Milli-Q system with Millipore Q-Gard 2/Quantum Ex 
Ultrapure organex cartridges was used for all cell culture, protein purification, and 
enzymatic reactions. E. coli seed culture was grown in 15 mL sterile tubes, and 
subsequently grown in Corning Fernbach flasks (2.8 L) with 3x deep baffles.  LB broth 
(Miller) and glycerol were obtained from EMD.  Isopropyl-β-D-thiogalactopyranoside 
(IPTG) and Kanamycin (Kan) sulfate were obtained from Gold Biotechnology. NaCl, 
CaCl2 and imidazole were obtained from Fisher Scientific. Lysozyme was purchased 
from RPI.  Benzonase was purchased from Sigma Aldrich.  PD-10 columns were 
purchased from GE scientific and equilibrated with 5 column volumes of storage buffer 
before use.  Ni-NTA agarose resin was purchased from Qiagen and pre-equilibrated 
with five column volumes of lysis buffer before use.  
A Symphony SB70P pH meter was calibrated according to the manufacturer’s 
specifications and used to monitor the pH of all solutions during adjustment. Cells were 
lysed using a 550 Sonic Dismembrator purchased from Fisher Scientific.  Optical 
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density (OD600) was determined using an Eppendorf Biophotometer.  All solutions were 
autoclaved or sterile filtered through a 0.2 μm filter.   
 
Buffers:  
lysis: HEPES (50 mM), NaCl (300 mM), imidazole (10 mM), glycerol (10% v/v), pH 8.0. 
wash: HEPES (50 mM), NaCl (300 mM), imidazole (30 mM), glycerol (10% v/v), pH 8.0. 
elution HEPES (50 mM), NaCl (300 mM), imidazole (300 mM), glycerol (10% v/v), pH 
8.0. 
storage: HEPES (50 mM), NaCl (150 mM), EDTA (1 mM), glycerol (20% v/v), pH 7.2. 
gel filtration: Tris (20 mM), NaCl (150 mM), glycerol (10% v/v), pH7.5. 
 
Protein Expression 
The cloning, expression and purification of Pik TEWT
19 and DEBS TEWT
20 have been 
previously reported and served as the templates for generating the corresponding 
cysteine mutants. The creation of Pik TES148C and Juv TEWT are reported in Chapter III 
of this Thesis. Pik TES148CH268X mutants were generated from a pET28 plasmid encoding 
Pik TES148C by substitution of the wild type codon 268 CAC using the QuikChange site-
directed mutagenesis (Stratagene) protocol. MBP-Pik TES148CH268R was generated by 
insertion of Pik TES148CH268R into a pET28 vector containing an N-terminal 6x His tag 
followed by the MBP protein and a TEV cleavage site. Identical protocols were used for 
the expression and purification of all Pik TE mutants.  
A starter culture was generated by inoculating 5 mL of LB broth containing Kan (50 
mg/L) with fresh transformants of E. coli (BAP1)21 cells containing the corresponding 
plasmids for expression of the respective PKS proteins and grown overnight at 37 ˚C. 
Following the overnight growth, the entire starter culture was subsequently used to 
inoculate an expression culture of 1 L of TB containing Kan (50 mg/L) and grown at 37 
˚C to an OD600 of 0.3-0.4. The expression cultures were then cooled to 18 ˚C and 
growth was maintained until an OD600 of 0.7-0.8 was reached, at which point protein 
expression was induced via addition of IPTG (350 µM) and the cultures were incubated 




Protein Purification   
All proteins were subjected to the following first round of purification: 
To retain maximum enzymatic activity, the following purification procedure was 
performed at 4 ˚C in less than 2 hours. Overexpression cultures were harvested by 
centrifugation (5,500 x g, 10 min, 4 ˚C) and cell pellets were suspended in 5 mL of lysis 
buffer per gram of cells via vortex. Cell lysis was accomplished by gentle agitation at 4 
˚C with 0.4 mg/ml lysozyme and 8 units/ml benzonase for 30 min followed by sonication 
on ice (1 x 10s with 50s rest periods). Cellular debris was pelleted by centrifugation 
(40,000 x g, 15 min, 4 ˚C), and the supernatant applied to 3 mL of Ni-NTA resin. After 
binding, the column was washed with 25 mL of wash buffer under gentle syringe 
pressure and the target protein was eluted with 15 mL of elution buffer. Protein 
containing fractions were assessed via their absorption at 280 nm, pooled, and buffer 
exchanged into storage buffer using a PD-10 column. Finally, protein containing 
fractions were determined via their absorption at 280 nm, pooled, flash frozen in liquid 
N2, and stored at -80 ˚C.  
 
Following purification by Ni-NTA chromatography, the relevant proteins were further 
processed for in vitro analysis: 
TEV cleavage of the MBP-tagged Pik TES148CH268R was accomplished by incubation of 
the fusion protein with the TEV protease (1:30 molar ratio of Pik TE to TEV protease) in 
storage buffer at 4 ˚C for 18 hours. After cleavage, the reaction mixture was passed 
over a small bed of Ni-NTA resin to remove the His-tagged MBP.  
Gel filtration chromatography of Pik TES148CH268Q was accomplished using 
HiPrep 26/60 Sephacryl S-300 HR column from GE Healthcare Life Sciences in gel 
filtration buffer set to a flow rate of 0.5 mL/min.  Protein containing fractions were 
assessed via their absorption at 280 nm, pooled, concentrated with a Amicon Ultra-15 
Centrifugal Filter (10 kDa cut-off), flash frozen in liquid N2, and stored at -80 ˚C. 
 
Pik TE acyl-enzyme formation 
To determine the ability of Pik TES148CH268R to be stabilized as the acyl-enzyme, we 
explored reaction conditions for optimum substrate loading. We anticipated alkaline 
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conditions favoring the transthioesterification reaction would provide the best results, 
ultimately a borate buffered solution at pH 10.2 provided the most consistent substrate 
incorporation. Final reaction conditions: 1:1 molar ratio of Pik TE to 1, 1.7% DMSO, 150 
mM borate pH 10.2 18 hours, RT. Analytical labelling reactions were assessed via LC-
HRMS was performed on an Agilent LC system (1290 series) coupled to an Agilent 
QTOF mass spectrometer (6500 series) using a Phenomenex Aeris Widepore 3.6μ C4 
50 x 2.10 mm column (serial 687169-3). Method: 0.4 mL/min, solvent A: H2O 0.1% 
formic acid, solvent B: MeCN 0.1% formic acid, 0% B 0-2 min,0-100% B linear gradient 
2-10 min, 100% 10-11 min, 0% B 11-12 min, 0-1 min were diverted to waste.  
  
Chemical lactonizations 
Optimum conditions for comparison of head-to-head lactonization efficiency of 4 and 5 
were based on total synthesis of structurally related 12-membered macrocycles10 and 
were performed on 12 μmol scale as follows. Seco-acid 4 or 5 (4 mg, 0.012 mmol, 1.0 
equiv) and reaction vial were azeotroped with PhMe (3x). THF was added (1mL, 0.012 
M) and cooled to 0 °C. Et3N (10 μL, 0.048 mmol, 6.0 equiv) and 2,4,6-trichlorobenzoyl 
chloride (8 μL, 0.048 mmol, 4 equiv) were added sequentially and the reaction was 
allowed to stir at RT for 1.5 hour. In a separate flask, 4-dimethylaminopyridine (14.7 mg, 
0.12 mmol, 10 equiv) was dissolved in PhMe (6 mL) and heated to 60 °C. After 1.5 
hours at RT, activated seco-acid was diluted in additional PhMe (1 mL) and this solution 
was added dropwise to the heated DMAP solution over 2.5 hour via syringe pump. After 
addition was complete, reaction was allowed to continue at 60 °C for another 0.5 hour 
before being cooled to RT and quenched with aq. NaHCO3 (sat). Organic and aqueous 
layers were separated, and organic layer was washed with brine and dried over MgSO4 
before concentration and HPLC analysis.  
 
Computational analysis of TE catalysis 
Pik TE structure preparation 
The wild type apo Pik TE structure was obtained from the RCSB Protein Data Bank 
(PDB: 1MNA).2 Structures for the wild type and mutant enzymes were prepared from 
WT Pik TE using PyMOL 1.3.22 Chain B of PDB file 1MNA and the crystallographic 
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water were removed, and 5 missing protein residues (T109-T113) were built into chain 
A using PyMOL 1.3. Parameters for the apo TE were generated using the antechamber 
module of AMBER 1423 with the widely tested Stony Brook modification of the Amber 99 
force field (ff99SB)24 force field. The initial substrate conformations were generated by 
modeling the linear hexaketide chain as neutral acyl serine or cysteine amino acids with 
N-terminal (-CO-CH3) and C-terminal (-NH-CH3) caps in an approximately cyclic 
orientation using the solved crystal structures of the derivatized macrolactone products 
as templates. The structure reported in reference 6 served as the template for Pik TE-1 
and Pik TE-2. The initial hexaketide confirmations were then optimized by performing a 
geometry optimization at the M06-2X functional25 level using the Gaussian 09 
package.26 The charges and parameters for the hexaketide substrates were then 
determined using the general AMBER force field (GAFF)27 with partial charges set to fit 
the electrostatic potential generated at the HF/6-31G(d) level by the RESP model.28 The 
charges were calculated according to the Merz–Singh–Kollman scheme29,30, using 
Gaussian 09. The N and C-terminal caps were then removed and the parameterized 
hexaketides were used to replace Ser148 of the TE to generate Pik TE modeled as 
acyl-enzyme intermediates. Parameter, topology, and coordinate files for the complex 
were compiled for molecular dynamics (MD) simulation using the tleap23 module. 
Following parameterization, the Pik TE models with bound hexaketides were immersed 
in a pre-equilibrated truncated cuboid box with a 8 Å buffer of TIP3P31 water molecules 
using tleap and the systems were neutralized by addition of explicit counter ions (Na+ 
and Clˉ).  
 
Molecular Dynamics simulations 
MD simulations were performed using the AMBER 14 package.23 A cutoff of 8 Å was 
used for all Lennard-Jones and electrostatic interactions. Water molecules were treated 
with the SHAKE algorithm such that the angle between the hydrogen atoms was kept 
fixed. Periodic boundary conditions simulated the effects of a larger system size. Long-
range electrostatic effects were modelled using the particle-mesh-Ewald method.32 Prior 
to performing the production MD simulations, the solvated systems were subjected to 
two steps each of minimization and equilibration to relax and correct any possibly 
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unrealistic arrangements: two minimizations were performed first over a total of 5000 
cycles each, with the method being switched from the steepest descent algorithm to 
conjugate gradient after 2500 cycles. The first minimization relaxed the positions of the 
solvent molecules and ions by imposing positional restraints on the solute by a 
harmonic potential with a force constant of 500 kcal mol-1 Å-2. Following the first 
minimization, a distance restraint of 2.3 Å between the hexaketide nucleophilic hydroxyl 
hydrogen and the Nε nitrogen of His268 was imposed and maintained throughout the 
second minimization, both equilibrations, and first production simulation, the restraint 
was then released for the second production simulation. This restraint maintains the 
hexaketide and the catalytic histidine residue –His268 acts as the general base–in an 
arrangement close to that calculated for the macrolactonization transition state, while 
allowing the hexaketide backbone to explore both reactive and non-reactive 
conformations. The restraint also served to minimize any potential biases resulting from 
the initial substrate positioning. After the distance restraint was imposed, a second 
stage minimization was performed on all the atoms in the simulation cell without 
cartesian atomic restraints. Post minimization, two equilibrations were performed. In the 
first equilibration step, a 0.1 ns MD simulation was performed with a constant pressure 
of 1 atm and a constraint of 10 kcal mol-1 Å-2 on the protein and substrate. The 
Andersen thermostat equilibration scheme was used to control and equalize the 
temperature by gradually increasing the system temperature from 0 to 300 K over the 
course of the first equilibration run. The system volume was then fixed and a second 
equilibration step was achieved with 2 ns MD simulation conducted without cartesian 
atomic restraints with a temperature maintained at 300 K using the Andersen 
thermostat.  
Post equilibration, two additional MD simulations were carried out utilizing the above 
conditions: Initially, a 50 ns simulation was performed with the aforementioned distance 
restraint intact to ensure proper shape complementarity of the TE active site for the acyl 
intermediate forced in a pre-catalytic state. Next, the substrate-protein distance restraint 
was removed and a final production simulation was run for an additional 500 ns. This 
portion of the simulation represents the conformation of both the substrate and the 
protein environment in the covalently bound Michaelis-Menten complex prior to reaction. 
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An integration time step of 2 fs was utilized with structural snapshots being extracted 
every 50 steps during both production simulations. The resulting production trajectories 
were analyzed using the cpptraj program in Ambertools14 employing the default options 
to describe hydrogen-bonding, hydrophobic interactions, and clustering analysis.  
 
QM Computational Details.  
Full geometry optimizations were carried out with Gaussian 0926using the M06-2X 
hybrid functional25 and 6-31+G(d,p) basis set. Solvation was considered implicitly 
through the PCM polarizable continuum model33 in order to better reproduce the 
electrostatic environment inside the enzyme active site (ε=4). The possibility of different 
conformations was taken into account for all structures. All stationary points were 
characterized by a frequency analysis performed at the same level used in the 
geometry optimizations from which thermal corrections were obtained at 298.15 K. 
Local minima and first order saddle points were identified by the number of imaginary 
vibrational frequencies. The quasiharmonic approximation reported by Truhlar et al. was 
used to replace the harmonic oscillator approximation for the calculation of the 
vibrational contribution to enthalpy and entropy.34 Scaled frequencies were not 
considered. Mass-weighted intrinsic reaction coordinate (IRC) calculations were carried 
out by using the Gonzalez and Schlegel scheme35,36 in order to ensure that the TSs 
indeed connected the appropriate reactants and products. Gibbs free energies (ΔG) 
were used for the discussion on the relative stabilities of the considered structures. 
Cartesian coordinates, electronic energies, entropies, enthalpies, Gibbs free energies, 
and lowest frequencies of the calculated structures are available below. 
Attempts to locate transition states for the initial covalent binding step (i.e. Ser/Cys148 
acylation) from thioester models of Pik TEWT and Pik TES148C were unsuccessful, due to 
the very flat topology found for the corresponding potential energy surfaces. Hence, 
very low activation barriers are expected for the initial substrate binding, and 
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Summary and insights 
 Due to advances in molecular techniques and the subsequent elucidation of the 
biosynthetic logic of polyketide diversification1,2, the past two decades witnessed an 
intense interest in the biosynthetic production of macrocylic polyketide analogs.3-7 
During this time, many research groups reported the production of large libraries of 
macrolactone analogs achieved through PKS engineering strategies.4-6 These PKS 
engineering efforts mainly employed canonical combinatorial biosynthesis techniques 
and targeted their modifications to the individual domain level to instill new functionality 
into the macrolactone ring. Three prominent examples were reported by Kosan 
Biosciences, highlighting the ability to generate libraries of polyketide analogs through 
modular PKS engineering.4-6 In these studies, AT and KR domain substitutions were 
engineered into modules 2, 5, and 6 of the 6-deoxyerythronolide B (DEBS) biosynthetic 
pathway and the engineered PKSs were expressed in heterologous Streptomyces or E. 
coli hosts to generate a suite of 6-dEB analogs. However, as evidenced in this seminal 
work, these engineering attempts employing combinatorial biosynthesis techniques 
often resulted in large decreases in product titers.8 This unintended consequence was 
exemplified by the <0.1 mg L-1 product yields from the double and triple mutant 
pathways versus the 20 mg L-1 from that of the wild type system.4 Thus, although these 
historical examples successfully generated inspiringly diverse arrays of macrolactone 
analogs, the associated decreased product yields renders these strategies as 
impractical for providing quantities sufficient for the drug discovery pipeline.8  
Convoluting the mechanistic interpretation of these decreased yields is the in 
vivo context in which these experiments were performed. Often times, the engineered 
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PKS system was expressed in a heterologous host and product confirmation was 
determined by LC-MS analysis of the resulting growth media1,2. Associated with this 
experimental design are two significant limitations: First, the application of LC-MS 
analysis for product confirmation, in contrast to isolated and structurally characterized 
products, provides ambiguity for the regio- and stereoselectivity of the reactions from 
the engineered catalytic domains as the reaction outcomes would be isobaric and 
inseparable from their mass spectrum. Secondly, the biochemical basis for the low 
yields or failed production of metabolites from engineered PKSs remains elusive. 
Typically, genetic modifications have been performed in early pathway PKS modules1-6, 
and it has remained unclear whether attenuated product formation stems from the 
engineered module or the downstream modules (or both) that must accept and process 
the resulting unnatural intermediates. Therefore, even if the engineered module or 
domain successfully performs its non-native functionality, the nascent polyketide chain 
must then be productively acted upon by the downstream core, β-keto processing, and 
thioesterase domains in order to produce the anticipated natural product analog. If this 
downstream processing fails, then the assembly line tethered elongation intermediate 
may be offloaded hydrolytically thus producing an unstable shunt product difficult to 
detect by LC-MS or isolate from the complex fermentation medium. Notably, we7-9 and 
others10,11 have previously shown that PKS TE domains function as flexible hydrolases 
when substrate macrolactonization cannot be achieved, resulting in substrate flux to 
intermediates not readily detected by LC-MS. Consequently, interpretation of in vivo 
PKS engineering studies using a binary system of analysis based on LC-MS detection 
of the fully mature product fails to provide insight into the catalytic point of failure if the 
anticipated product is not detected. Motivated by this gap of knowledge, the studies 
reported in this thesis seek to provide further insight into the structural and mechanistic 
underpinnings that govern catalysis in engineered PKSs in efforts to improve their 
potential for the biosynthetic production of polyketide analogs.  
Towards this goal, we have performed experiments focused on providing a more 
general framework for rational engineering of efficient PKSs through targeted 
investigations designed to probe the catalytic details of individual domains.  
Interrogating the substrate flexibility of the late stage PKS module PikAIII-TE12-14 with 
110 
 
unnatural pentaketide analogs designed to simulate “combinatorial biosynthesis” 
provided key insights into the catalytic bottlenecks encountered within engineered 
PKSs. Using a targeted in vitro approach, we reported a strict substrate stereoselectivity 
inherent to PikAIII-TE, resulting in the failed processing of an epimeric pentaketide 
analog containing an (S)-configured nucleophilic hydroxyl group. As the only change 
from the natural Pik pentaketide is epimerization of the C-9 hydroxyl group that serves 
as the nucleophile during macrolactonization, we reasoned, a priori, that the substrate 
would detrimentally affect the TE domain responsible for ring formation. TE 
stereoselectivity has been observed previously from in vitro reactions of DEBS TE with 
a series of unnatural DEBS heptaketide substrate mimics. The DEBS TE displayed 
strict stereoselectivity for the natural (R)-configuration of the substrate nucleophilic 
alcohol and exclusively hydrolyzed the unnatural (S)-stereoisomer15. NMR and MS 
characterization of the reaction products from our panel of stereoisomeric Pik 
pentaketides showed that the intermediates had been extended; therefore the KS 
domain was at least partially competent in processing these analogs. Additionally, as 
the Pik TE is able to cyclize β-keto analogs of the natural hexaketide to yield 3-keto-10-
dml13,16 we expected to observe 3-keto macrolactones if the KR was compromised17-19, 
but KS and TE domains remained functional.  
We hypothesized that the isolated shunt products resulted from substrate stalling 
and premature off-loading from the PKS via hydrolysis and subsequent decarboxylation. 
Analysis of these extended but linear off-loaded intermediates suggests that the TE is 
acting as the dominant catalytic bottleneck to the formation of macrocylic products. The 
inability to attain a total mass balance for the stereoisomer substrate panel and the low 
recovery of shunt products from each reaction is attributed to the additional facile 
degradative pathway possible through the TE domain. PKS TE domains serve as 
flexible hydrolases when cyclization is impaired.7,10 Thus, we reasoned that a portion of 
the pentaketides were extended and off-loaded as the unstable β-hydroxy hexaketide, 
which subsequently degrades through intramolecular hemiketalization and dehydration 
pathways14,20.  
Initial in vitro biochemical characterization of the DEBS TE10,11 provided further 
evidence for the relatively high substrate tolerance of PKS TEs for acylation and 
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hydrolysis, as terminally (omega) hydroxylated fatty acids and substrates resembling 
simplified DEBS heptaketides were all hydrolyzed by DEBS TE. However, the ability of 
PKS TEs to cyclize substrates other than their native linear intermediates has proved to 
be much more limited. In fact, TE mediated macrolactonization has only been observed 
in a select few studies.7,15,20-27 In addition to their native substrates, Pik TE has been 
shown to catalyze macrolactonization of C-3 methyl  and NBOM protected derivatives20, 
though not C-7 reduced analogs.7,22 DEBS TE has been shown to catalyze 
macrolactonization of unnatural mimics of the DEBS heptaketide.15,25 However, there 
are no reports of either the Pik or DEBS TEs catalyzing macrolactonization of a 
substrate containing a nucleophilic hydroxyl group with an unnatural, epimerized (S)-
configuration. When probed for the ability to form an epimeric heptaketide mimic of 6-
dEB , the DEBS TE displayed a high level of stereoselectivity for the natural (R)-
configuration, and exclusively hydrolyzed the unnatural (S)-stereoisomer15, adding to 
the observations in this study for strict stereospecificity in TE catalyzed 
macrolactonization. Indeed, synthesis of the corresponding C-11-epimerized hexaketide 
and subsequent probing of the Pik TE domain provides direct evidence for the strict 
stereoselectivity of Pik TE. This stereoselectivity confirms the suspected TE bottleneck 
for macrolactone formation and explains the loss of macrolactone formation in PikAIII-
TE reactions containing the diasteromeric pentaketides. 
Having demonstrated the critical nature of the TE domain in the processing of 
unnatural substrates, we hypothesized that the TE domain is acting as a dominant 
catalytic bottleneck in PKS engineering strategies that utilize the rearrangement of 
upstream catalytic domains as these result in intermediates that may fail to be 
processed by the downstream incompatible TE domain. To explore this concept, we 
generated a series of hybrid type I PKS modules with TE domains from three related 
biosynthetic pathways and tested each for catalytic activity with full length substrates to 
simulate the final steps in engineered PKS catalysis. Remarkably, we were able to 
achieve robust catalysis with non-native module/substrate pairs when the hybrid module 
was paired with a competent TE domain. These results expand upon our previous 
findings and demonstrate the key role of the TE domain in the processing of unnatural 
intermediates. Of note, the results reported in this study are in agreement with similar 
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work performed in fungal iterative polyketide synthases (iPKSs) which identified the TE 
domain as a key gatekeeper in the production of fungal polyketides.28-31 Furthermore, 
our results with the Pik hexaketide indicate that the identity of the TE domain may also 
alter the sequence of catalytic events that occur in engineered PKS modules. This is 
evidenced by the product distribution in reactions pairing the Pik hexaketide with Ery 
Mod6-Pik TE and Ery Mod6-DEBS TE to generate predominantly narbonolide or 3-
hydro-narbonolide, respectively.  
The mechanism for this unexpected consequence from exchanging of TE 
domains is unclear at this point. It is tempting to speculate that the identity of the TE 
domain can interfere with the canonical vectorial processing of the PKS assembly line 
through premature loading of the elongation intermediate that most closely resembles 
its native substrate. Although the cryo-EM studies of PikAIII indicated that the sequence 
of interactions taking place between the PKS catalytic domains and the ACP-tethered 
intermediate occurs in an orchestrated and linear fashion32,33, I note that these studies 
were performed using wildtype PikAIII with its native substrate. Perhaps PKS assembly 
line processing follows a more diffuse path in which the loaded ACP samples all 
available catalytic domains in search of the interaction which provides the highest 
degree of affinity. Notably, this paradigm indicates the molecular identity of the ACP-
tethered elongation intermediate could impact the binding affinity, and thus 
subsequently, the length of time the elongation intermediate spends within each 
catalytic domain. In the context of native assembly line processing, this dynamic 
sampling would be finely tuned for proceeding in the catalytic sequence that leads to the 
fully mature natural product through variations in the individual domain and elongation 
intermediate binding affinities. However, in the processing of unnatural substrates, the 
native sequence could be perturbed if the order of binding affinities is rearranged such 
that the ACP-tethered elongation intermediate prematurely resides in an alternative 
catalytic domain. Thus since narbonolide is the native product of Pik TE and 3-hydro-
narbolide more closely resembles the native product of DEBS TE (6-dEB contains a C-3 
hydroxyl group), reactions containing Ery Mod6-DEBS TE follow the anticipated 
catalytic sequence to include KR mediated reduction while the reactions with Ery Mod6-
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Pik TE result in the premature transfer of the ACP-tethered elongation intermediate to 
the Pik TE domain prior to processing by the KR domain.  
Stabilization of the Pik hexaketide allowed for direct probing of the excised Pik 
TE domain and the following confirmation of the TE catalytic bottleneck due to strict 
substrate stereoselectivity. Remarkably, initial engineering attempts identified a single 
active site mutation within the Pik TE that imparts both increased substrate flexibility 
and catalytic efficiency, resulting in a macrolactonization catalyst capable of forming 
diastereomeric macrolactones. Investigating the potential of TE engineering within the 
context of full module processing through direct comparison of PikAIII-TEWT and PikAIII-
TES148C with a panel of stereoisomer Pik pentaketides demonstrated the success of this 
approach as a 0.2 millimole scale reaction resulted in the production of two new 
diastereomeric macrolactone products, 11-epi-10-dml and 3-keto-11-epi-10-dml. The 
1:1 isolation of the reduced and unreduced macrolactones from reactions with PikAIII-
TES148C indicates that the TE was indeed responsible for the failed catalysis using WT 
PikAIII-TE, as the KR domain retained a sufficient level of activity towards the unnatural 
intermediate. This demonstration of TE engineering offers a potential means for 
increasing the substrate flexibility of biosynthetic pathways for the production of natural 
product analogs.  
Unfortunately, one hurdle in the general application of Pik TES148C in full module 
catalysis is the increased levels of substrate hydrolysis observed with PikAIII-TES148C. 
We had originally found that thio- or oxoester choice determined the catalytic route of 
the hexaketide in the presence of PikAIV in vitro, with thiophenol and N-
acetylcysteamine thioesters having a 10:1 preference for either full-module processing 
or direct cyclization, respectively. Thus, we reasoned that the low yields from the 
PikAIII-TES148C reactions with the C-9-epimerized pentaketide are likely due to direct 
loading of the S148C TE domain and subsequent hydrolysis. Indeed, control reactions 
confirmed (i) the S148C mutation overrides the KS preference previously enjoyed by 
thiophenol thioesters (ii) enzymatic reactions performed without extender unit or 






 The results from the studies contained within this thesis serve to highlight the 
critical nature of performing targeted, in vitro investigations into the catalytic functioning 
of engineered PKS modules. Moving forward, it is of paramount importance to expand 
our growing understanding of the substrate flexibility of each particular PKS catalytic 
domain in order to provide a clearer blueprint for future PKS engineering techniques. 
Particularly productive will be the continued application of synthetic chemistry to provide 
full length native substrates, and analogs thereof, to probe the flexibility of late stage 
PKS modules. This strategy was successfully employed to reveal the unintuitive role of 
the TE domain as a dominant catalytic bottleneck in the processing of unnatural 
substrates. Identification of these gatekeeper domains should enable future efforts to 
focus on the engineering of each bottleneck in order to increase the efficiency of 
engineered PKS pathways for the production of polyketide analogs.  
Although we achieved promising results by employing engineered TE domains 
within PKS modules, it is clear that the other core catalytic PKS domains play a role in 
substrate gating as well. This was particularly noted in the hybrid TE PKS module 
reactions pairing Juv Mod6 TE hybrids with the Pik hexaketide, as no choice in TE 
resulted in significant product formation. Since all three TE domains were able to 
produce at least one of the anticipated products when paired with DEBS Mod6, we 
interpret the failed Juv Mod6 TE hybrid reactions to indicate an additional catalytic 
bottleneck located elsewhere in the module. Thus, future efforts will need to focus on 
identifying these additional catalytic roadblocks through the use of full length substrates 
to probe individual modules and excised domains directly. Application of this strategy 
should provide additional insights into the structural and mechanistic parameters that 
govern PKS function in a manner similar to the identification of the TE domain 
bottleneck from the studies reported in this thesis. 
Our results lay the foundation for the application of TE engineering to increase 
the substrate flexibility and catalytic efficiency of both excised TE domains and 
engineered PKS modules. The remarkable results achieved with Pik TES148C suggest 
that Ser to Cys mutations of the catalytic triad within type I PKS TE domains may 
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provide macrolactonization catalysts capable of producing difficult to form macrocycles. 
This would have significant impacts on the field of natural products synthesis as current 
chemical macrolactonization methodology is often ineffective in the key ring-closing step 
of linear natural product intermediates.34 Although many efficient macrocyclization 
methods have been developed, the lactonization of seco-acids is still a frequently 
utilized approach to obtaining macrocycles35. Unfortunately, these classical approaches 
to the ring-closing step in the synthesis of natural products often require significant 
experimental optimization and suffer from complex synthetic sequences, high dilution 
conditions, etc.34 In contrast, Pik TES148C catalysis operates using 1 mol % enzyme in 
water at room temperature, avoiding large volumes of dry organic solvents, heating, and 
expensive Yamaguchi or Shiina reagents. Furthermore, cryptic substrate conformational 
and stereochemical requirements are critical for successful chemical 
macrolactonization. These experimental limitations are highlighted from the pioneering 
total synthesis of erythromycin A in which Woodward and co-workers successfully 
generated the 9-dihydroerythronolide macrolactone only after screening 17 differentially 
protected seco-acids.36 The need for specific protecting group arrays to promote 
macrolactonization was rationalized through conformational biasing of the seco-acid37, 
and thus suggests that any substrate analogs would require their own extensive 
optimization. Consequently, the implementation of engineered TE domains as 
macrolactonization catalysts offers great potential value for the chemoenzymatic 
synthesis of natural products. Future efforts will focus on performing analogous Ser to 
Cys mutations within a diverse array of TE domains responsible for forming both 
macrolactones as well as macrolactams and testing them for the ability to more 
efficiently generate valuable macrocyles versus the current chemical macrocyclization 
routes.  
A second promising implementation of TE domain engineering is in the 
incorporation of optimized TE domains within engineered PKS pathways as a means for 
increasing the efficiency of the biosynthetic production of polyketide analogs. It is 
tempting to speculate on the potential benefits an optimized TE domain would impart on 
the 6-dEB analog combinatorial biosynthesis studies mentioned previously. If the low 
product titers reported from this work were in fact due to incompatibilities of the native 
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DEBS TE with the unnatural elongation intermediates, then it is possible that a 
contemporaneous engineering of the TE domain may alleviate these detrimental effects.  
This concept was explored through the generation and analysis of hybrid TE PKS 
modules in Chapter II, and the current findings could be advanced by performing these 
TE domain swaps in vivo for comparison with the historical experimental design. 
Introduction of TE domains with cysteine nucleophiles into engineered PKS pathways 
also offers potential for increasing the product diversity achievable with these 
engineered systems. However, if the tendency towards premature loading of elongation 
intermediates observed from the in vitro reactions with PikAIII-TES148C is recapitulated in 
vivo, then additional TE engineering with the goal of tuning the reactivity for the 
acylation step will be required. 
Recently, Schaffer et al. reported a TE domain with a native cysteine nucleophile 
critical to the cyclization of a strained β-lactone ring in the obafluorin (Obi) nonribosomal 
peptide pathway.38 Of note, an analogous cysteine to serine mutation in the Obi TE 
resulted solely in the hydrolysis product, further implicating the catalytic advantage of a 
cysteine TE in the cyclization of strained ring systems. In this study the authors 
evaluated the prevalence of Cys containing TE domains by analyzing the complete 
annotated Pfam database and the top 20,000 hits from a standard protein BLAST 
search. Survey of the TE protein family (PF00975) in Pfam indicated that 6.8% of 
members possessed a cysteine nucleophile while the remainder contained the more 
prevalent serine. Of the BLAST results, 13,944 possessed a canonical serine. 
Examples of modular type I polyketide TE domains containing cysteine active site 
nucleophiles are notably rare.39 Furthermore, at the present time we are unaware of any 
naturally occurring macrolactone forming TE domains that contain a cysteine 
nucleophile. We note that the TE domain from the type I PKS fluvirucin B1 naturally 
contains a cysteine nucleophile, however, Flu TE catalyzes the formation of a 
macrolactam since the acyclic precursor contains an amine intramolecular nucleophile 
arising from the β-alanine derived starter unit.40  
We hypothesize that the lack of naturally occurring type I PKS TE domains 
possessing a cysteine nucleophile can be attributed at least in part to the potential 
negative effects the more nucleophilic cysteine would impart on the vectorial channeling 
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of intermediates within polyketide synthase assembly lines. As shown in Chapter III, Pik 
TES148C is less sensitive to the choice in thio- and oxoesters for substrate loading, 
indicating a higher rate of acylation from the more reactive cysteine nucleophile. 
Furthermore, PikAIII-TES148C when incubated with the native Pik pentaketide produces 
both 10-dml and the unreduced 3-keto-10-dml suggesting that the cysteine TE domain 
is able to outcompete the KR domain in the native catalytic sequence. The precise 
reactivity of the active site residues within each individual catalytic domain has been 
finely tuned in order for the assembly line to function in a cohesive manner to produce 
the fully mature natural product. Therefore, incorporation of a cysteine active site TE 
domain into a native type I PKS pathway may interfere with the productive catalytic 
sequence through inappropriate and/or premature loading of biosynthetic intermediates. 
Given the significant results obtained with Pik TES148C, we are currently in the process of 
curating all annotated TE domains involved in macrolactone formation in search of 
those that may contain a cysteine nucleophile. Further studies will focus on delineating 
the biosynthetic parameters that select for cysteine or serine active site residues. 
Moving forward, investigations employing x-ray crystallography and cryo-electron 
microscopy focused on full modules and excised domains in conjunction with full length 
substrates will begin to unveil the structural parameters that govern substrate 
processing within the context of engineered PKS systems. Supplementing these 
experimental techniques with computational modelling will provide further insights into 
the conformational and thermodynamic effects resulting from specific engineered 
catalytic domains. These advanced structural studies should shed light on the 
parameters that determine the sequence of catalytic events in the processing of 
unnatural substrates and thus advance our understanding of the vectorial channeling of 
intermediates within polyketide synthase assembly lines in both engineered and native 
biosynthetic pathways. This foundational knowledge will in turn better equip the PKS 
community for designing de novo pathways capable of efficiently generating high value 
polyketide analogs. Due to the critical nature of the TE domain discovered by the 
experiments performed in this thesis, current efforts in the Sherman lab are focused on 
capturing the Pik TE in complex with its native substrate, as well as with full length 
analogs, as a co-crystal structure for x-ray crystallography. We anticipate that analysis 
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of the bound acyl-enzyme complex will provide structural insights useful for the precise 
engineering of non-native functionality into PKS TE domains. Optimization of 
crystallization conditions suitable for the acyl-enzyme intermediates generated in 
Chapter IV is currently ongoing.  
While additional biochemical studies of excised domains and full-modules with 
full length analogs of native substrates are necessary to support and expand our 
understanding of PKS function, it is becoming apparent that efficient production of 
specific, designer macrolide analogs will require significant pathway engineering. 
However, production of a desired natural product analog should be obtainable through 
the following workflow: (i) a targeted domain is engineered to perform an unnatural 
function (ii) downstream modules are biochemically characterized in vitro with the 
resulting unnatural polyketide in order to identify bottlenecks (iii) catalytically inefficient 
domain(s) are engineered with the goal of restoring effective processing to generate 
unnatural products. Indeed, as noted in a recent review by Weissman41, it is perhaps 
more realistic to envision the future application of PKS engineering as a synthetic 
biology tool for producing specific, high-value natural product derivatives through 
targeted reprogramming of modular type I polyketide pathways than generation of 
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